Customer support for pharma CRM affects how quickly problems are solved, how confidently users work in the system, and how easily the CRM can adapt as the commercial organisation changes. Without proactive and reliable customer support, unresolved problems can put CRM projects at risk.

That’s why customer support should start way before go-live.

A new pharma CRM has to be configured around the company’s processes, loaded with usable data and understood by the people who will work in it. 

Reps then need help as the system goes live. Months later, administrators may need to change an existing setup, add users, import data or ask the vendor for help with work the customer can’t handle internally.

For mid-sized pharma companies without large internal CRM teams, the quality of that support can make a major difference to the day-to-day value of the CRM system.

Giving customers access to a ticketing portal is only one part of it.

What does good pharma CRM customer support actually include?

Good pharma CRM customer support covers different needs at different stages of the CRM lifecycle.

Some requests are straightforward software problems. A user can’t log in, a function behaves incorrectly, or a bug needs technical investigation.

Others require knowledge of the customer’s CRM setup and commercial processes. An administrator may need help changing an existing workflow, a sales manager may not understand why information is appearing in a particular way, or a new market may need support using an established corporate setup.

The support model needs to accommodate all the specific requirements of a pharma company.

Customers should also know where standard product support ends.

Platform administration, significant configuration work, data imports, new analytical outputs or advisory work may not be included in the basic licence. That’s entirely reasonable if the boundaries, what package tiers include, and pricing are all clear before the customer needs them.

Why is pharma CRM customer support so important?

CRM problems rarely stay isolated.

If a rep can’t complete a call report correctly, the customer history can become incomplete. If users interpret a field differently, the information captured across the field force can become inconsistent. If an outdated process can’t be changed easily, people may begin working around the CRM.

Those workarounds can eventually become a bigger problem than the original issue.

Support also affects user confidence. Reps who can get useful answers quickly have less reason to abandon the agreed process, and administrators who know where to go for help can resolve problems before they start spreading and getting worse.

There is another important effect: knowledge transfer.

A pharma company should become more capable of running its own CRM as its administrators gain experience. Good vendor support helps them do that rather than creating unnecessary dependence by keeping routine knowledge locked away on the vendor’s side.

Stage 1: Pharma CRM support during implementation

Customer support should already be operating while the pharma CRM is being implemented.

The customer and vendor are making decisions about workflows, user roles, data, and field processes that will affect the system after launch. Some questions only become visible once users begin working with realistic data and day-to-day scenarios.

Training alone doesn’t solve that.

A process may make sense during a workshop but fail to work as intended in real-world use. Reps might all misunderstand the same step, or an administrator might find out that a particular setup doesn’t work as expected.

The support route needs to feed that information back to the vendor quickly, so the team can resolve the issue.

Companies should also agree who handles what before rollout begins. 

Reps need to know where to ask for help and internal administrators need to be clear about which requests they can resolve themselves and which should be sent to the vendor.

Stage 2: Pharma CRM support at rollout and go-live

Go-live can create a temporary spike in support demand.

Users are working with the live CRM, real customers, and real healthcare data while trying to continue doing their normal jobs. Problems that never appeared during testing can emerge and need to be quickly solved.

At the moment of rollout, the customer support team needs to separate several different issues:

Treating every request as the same type of ticket just slows everyone down.

Go-live support also provides useful evidence about the rollout itself. If multiple users ask the same question, training may need improving. If one workflow repeatedly causes confusion, the process itself may need to be changed.

Stage 3: Pharma CRM support during ongoing use

The CRM has to keep working after the project team has moved on.

Circumstances don’t remain static: new field reps join, people change roles, and territory structures change. Then new products launch, new markets are added, and commercial processes evolve.

Some changes can be handled internally but others need vendor involvement.

Buyers therefore must look beyond implementation when comparing CRM vendors. A system may be straightforward to launch but frustrating to own if routine support is slow or every small change becomes a new consulting project.

Before signing the contract, check who provides ongoing support, what the licence includes, and what additional work costs. Use the vendor checklist below for reference because these details become much harder to negotiate once the CRM is already running.

What should a pharma CRM service desk actually handle?

A pharma CRM service desk should give users one reliable place to report product problems and request help.

Typical requests include:

• login and access problems
• errors and unexpected system behaviour
• questions about existing functionality
• technical incidents
• problems requiring escalation to specialists

The service desk should not simply forward tickets.

A user might report that “the CRM is broken” when the underlying problem is a configuration rule, incorrect data or misunderstanding of the process. First-line support needs enough knowledge to identify where the request belongs.

Ticketing also creates a useful record of what happened, how serious it was, what was done and how the problem was resolved.

Repeated tickets can reveal wider problems too. 

Ten users asking the same question may indicate a training or usability issue that should be fixed once rather than answered repeatedly.

What should pharma CRM support SLAs and escalation cover?

Support SLAs should make clear what happens when something goes wrong.

A minor issue affecting one optional function shouldn’t receive the same response as a problem preventing an entire field force from working.

At minimum, customers should understand:

For example, Inception CRM provides standard support with every licence through phone, email, WhatsApp, Microsoft Teams and its ticketing system. Critical issues have free 24/7/365 on-demand assistance.

Buyers should understand arrangements like these before an urgent problem occurs.

Stage 4: Pharma CRM support for change management

Not every support request involves something being broken. Sometimes change management is the driver, with changing business needs requiring customer support from the CRM vendor.

A company may need help updating rep territories, importing HCP and HCO data, or carrying out work that its own administrators don’t have the time or expertise to handle.

These requests sit between ordinary technical support and a larger implementation project.

Customers should know which side of that boundary each request falls on.

Flexible operational-support packages can help because demand rarely stays constant. A company may need more assistance during rollout, less after administrators gain experience and another burst of support when a new market or process is introduced.

For multi-country organisations, a shared support pool can also make more sense than forcing each affiliate to purchase an identical service package.

What do pharma CRM vendors and customers often get wrong about support?

Weak support models aren’t always caused by the vendor. Pharma companies can create problems themselves if they fail to plan how the CRM will be supported after launch.

The best support relationship avoids both sets of problems.

The vendor retains enough customer knowledge to understand the system properly, while the pharma company maintains internal ownership and becomes more self-sufficient over time.

What should pharma companies ask about CRM support before choosing a vendor?

Support should be evaluated before the CRM contract is signed.

Ask:

• What customer support is included with the CRM licence?
• Who will be our regular contact after implementation?
• Which support channels are available?
• How are critical problems escalated?
• What does the SLA actually guarantee?
• Which requests count as standard support?
• What work costs extra?
• Can additional assistance be bought as a predictable allocation?
• Can several countries share the same support allocation?
• Can the support level change as our internal team becomes more experienced?

These answers also affect total cost.

A CRM with a competitive licence price can become expensive if routine changes repeatedly require separately scoped consulting work.

How does Inception CRM customer support work?

Inception CRM separates standard SaaS support, which is included with every licence, from optional operational assistance for customers that want the Inception team to carry out additional work.

This keeps routine product support separate from additional hands-on work that some customers want the vendor to perform for them.

Support during implementation and rollout

Inception implementations are delivered directly rather than passed to a third-party integrator.

Implementation covers the agreed work required to prepare the CRM for use, including configuration, data loading, and end-user training.

That direct and personal relationship continues after launch, so the people supporting the customer are not starting from scratch once the system goes live.

As the customer’s own administrators become more experienced, they can take over more routine management while retaining access to Inception when additional help is required. naturally, this decreases service costs at the same time.

Extra operational support when customers need it

Support demand does not stay constant after rollout.

Some customers want Inception closely involved in administration and day-to-day changes. Others prefer to manage most work internally and use additional assistance only when something falls outside their own capacity.

Inception therefore offers optional operational-support packages:

Larger organisations can also use a corporate support pool rather than assigning separate packages to individual markets.

That allows the available hours to be used across countries and different types of support work according to where demand is highest.

This can be particularly useful during multi-country rollout, when one affiliate may need substantial help while another is already largely self-sufficient.

The support level can then be reviewed as the organisation develops greater internal capability.

Good pharma CRM support should make customers more self-sufficient

Without strong customer support, even a well-chosen pharma CRM project can fail. Poor support can slow issue resolution, undermine user confidence, and encourage workarounds. The best support model helps customers become more self-sufficient while keeping expert help available.

Users need fast help when something is wrong. Administrators need access to people who understand the platform when they reach the limits of their own knowledge. Commercial teams need a practical way to request additional work when business requirements change.

At the same time, the customer should gradually become more capable of handling routine administration itself.

That’s why customer support for pharma CRM deserves the same scrutiny as functionality, implementation and price when companies compare systems. Check how each vendor supports implementation, go-live, ongoing use, change requests, and critical issues.

Ask Inception CRM to walk you through the support included with your licence and the options for additional operational assistance. If reliable customer support matters to you, it’s worth having a conversation with us.

Christopher Crawford is Head of Marketing at Inception CRM. He writes about the real-world strengths, weaknesses, and trade-offs of CRM, B2B, and B2C software, helping teams make clearer, more informed technology decisions.

FAQ: Pharma CRM customer support

The post Customer support for pharma CRM: what good customer service should actually include appeared first on Inception CRM.

That creates a practical problem for commercial teams. The strategy can be organised around the account, but the CRM still presents the customer mainly as a collection of fragmented HCP records.

A rep can know an individual specialist extremely well and still have only part of the picture. Other clinicians might influence decisions within the organisation. Pharmacy, procurement, access, management, or other stakeholders may matter. Several people from the pharmaceutical company might also be working with different parts of the same account — which is exactly how chaos is born if not handled correctly.

So, account-first commercial model specifically needs HCP/HCO information that is organised around the account as well as the individual.

At a glance

A strong pharma key account management approach should help commercial teams:

• Understand important HCPs within the organisations and networks around them
• See relationships between HCPs, HCOs, and other relevant stakeholders
• Coordinate several people working with the same account
• Connect account priorities to field activity and follow-up
• Retain what the company learns across multiple interactions
• Keep ownership clear when actions move between colleagues
• Judge account progress by more than the number of activities completed

Why pharma key account management is moving beyond individual HCP selling

Pharma KAM adds an account-level view to traditional HCP-focused selling, connecting individual customer relationships with the wider organisation and the people involved in it.

Key account management doesn’t make individual HCP relationships irrelevant, but instead it adds an account-level view around them.

A strategic account might contain several HCPs, departments, locations, decision-makers, and internal relationships and the pharmaceutical company might also have several people working around it, each with different responsibilities. This means that an account plan needs to connect individual customer relationships with the wider organisation, its relevant stakeholders, the objectives being pursued, and the work required from different members of the commercial team.

The difference between HCP-focused management and account-first management can be seen quite clearly:

The account view doesn’t replace the HCP view, but instead connects it to the surrounding organisation and wider context.

A key account is not simply a bigger HCP record

Adding twelve HCPs to an HCO record doesn’t automatically create a useful key-account view.

Consider a hospital account with twelve commercially relevant HCPs.

Two are particularly influential within the therapy area, one chairs a hospital committee, and another works closely with pharmacies. Three are regular prescribers but have little influence beyond their own practice. One specialist also holds a position at another hospital. Several people from the pharmaceutical company have spoken to different members of the account during the previous six months.

A list of twelve names tells the KAM very little about that structure.

The team needs to understand how those people relate to the organisation, what roles they play, which relationships matter to the current account objectives, what activity has already taken place, and who inside the pharmaceutical company is responsible for what happens next.

The individual HCP profiles still matter but the account view gives them full context.

Individual HCP profiles → HCP/HCO relationships → account structure → shared customer knowledge → coordinated account activity

HCP and HCO relationships need to be visible inside the pharma CRM

A pharma CRM for key account management needs to show those organisational relationships clearly.

An account-first pharma CRM should connect individual HCP information with the organisations, stakeholders, activity, and responsibilities around the wider account.

Healthcare professionals don’t always belong to one neat organisational unit. Putting one organisation into a single workplace field just can’t represent that properly.

One HCP can play different roles in different accounts

A cardiologist works at both a university hospital and a private specialist centre. Within the hospital, she contributes to a multidisciplinary team and has an organisational role relevant to the account. At the private clinic, the commercial relationship is mainly based around her own clinical work.

The HCP is the same person, but the account context is not limited to just that HCP.

A KAM looking at the hospital should be able to see that HCP among the relevant people around the organisation. A rep looking at the HCP should also be able to understand their affiliations and the account context attached to each one.

That’s why structured HCP/HCO relationships are more useful than simply storing larger quantities of customer data.

For an immediate example, Inception CRM’s HCP Management functionality connects customer information with organisational context and keeps relevant customer activity available around the HCP profile.

Pharma stakeholder mapping should reflect what teams learn in the field

Pharma stakeholder mapping is useful when it helps teams understand who matters within an account, why they matter, and how that should affect commercial activity.

One person may be important because of clinical influence. Another may matter because of their organisational responsibility. A third might become relevant because of a particular account objective. The categories and relationships will differ between companies, therapy areas, markets, and accounts.

They can also change.

Someone who appeared peripheral or unimportant six months ago may take on a new role. An influential HCP might suddenly leave the organisation. A new stakeholder can enter the account. An assumption about who matters may turn out to be badly wrong after several field interactions.

That means stakeholder information works best when it’s connected to customer activity that can confirm, challenge, or update it.

A static account map prepared at the beginning of the year will gradually become less and less useful if new field knowledge never reaches it or isn’t incorporated.

The CRM doesn’t needs to preserve enough structured information for the team to understand who is connected to the account, what the relationships are, and why those relationships matter.

Shared pharma accounts need clear ownership across the team

Shared pharma accounts need clear ownership because several colleagues may work with different HCPs and stakeholders inside the same organisation.

A KAM can coordinate the account while territory reps maintain relationships with individual HCPs, and managers review progress. Other authorised colleagues can have their own responsibilities around the same organisation.

Fragmentation is the obvious risk here.

A customer asks one person for information, that colleague forwards an email to somebody else. The second person makes a private reminder. A week later, the KAM sees the customer again but hasn’t a clue whether the request was ever completed.

A follow-up can cross several internal roles

During a meeting with a hospital account, a KAM learns that one specialist wants a follow-up conversation on a specific approved topic but the relevant territory rep already has the stronger relationship with that HCP.

The useful workflow is simple:

customer requirement → CRM task → named owner → status → completed action → retained account history

Without structured ownership, the same process can become:

customer requirement → email → forwarded message → personal reminder → uncertain status

That difference matters more as the number of people around an account grows.

Customer knowledge shouldn’t depend on one colleague having to remember who promised what.

Inception CRM’s Task Management functionality is designed to solve such issues by coordinating tasks, requests, and follow-ups across teams and shared accounts, with configurable ownership, status, workflows, and comments. That’s how every follow-up gets done, task status is clear, and everyone knows who’s responsible for what.

Customer request → email → forwarded email → personal reminder → unclear ownership

vs.

Customer request → CRM task → named owner → status → completed action → account history

Pharma key account management strategy has to influence field activities

For an account plan to have value, it has to influence everyday commercial activity.

Pharma teams can spend considerable effort defining account objectives, stakeholders, risks, and priorities, but if that information remains in a presentation reviewed every few months, field users still make their daily decisions elsewhere.

If several HCPs within an account have different priorities, that should influence field planning. If an important action has already taken place elsewhere in the organisation, another user should be able to see it before planning the next interaction. If the account strategy changes, responsibilities and activity should be able to change with it.

This is also why key account planning and territory planning should not be treated as identical.

Territory planning determines how field resources are deployed across customers and geography.

Key account planning looks more deeply at what the organisation is trying to achieve with a particular strategic customer and how the stakeholders around that customer affect the work required.

The two processes should support one another without becoming the same process.

A pharma sales planning system can help translate customer priorities into actual field coverage, while the account view provides the wider context for why those priorities matter.

More activity does not necessarily mean a stronger key account

High activity isn’t proof that a pharma key account is being managed well; the activity also needs to be coordinated around the account.

Imagine that a hospital receives ten interactions from a pharmaceutical company during one month. That might represent well-coordinated execution: several people working against a shared account objective, with each interaction building on what came before.

But it might also mean some crazy nonsense like five colleagues independently contacting related stakeholders without knowing what the others have already done.

The activity count is identical but the quality of account management is definitely not.

Calls, visits, meetings, emails, and completed tasks still matter. They simply make more sense when viewed within the wider account.

Before another interaction is planned, users should be able to see whether something relevant has already happened elsewhere in the organisation and whether another colleague is already dealing with it. The same context helps managers distinguish productive activity from activity that is repetitive, poorly coordinated, or unnecessary.

KAM knowledge should survive changes in people and territories

Pharma KAM knowledge needs to remain accessible when account managers, reps, territories, or responsibilities change.

An experienced KAM knows which relationships matter, how responsibilities are distributed inside the organisation, what previous discussions established, where an account has changed, and which assumptions are wrong.

That knowledge has value way beyond the individual employee.

People change roles, territories are reorganised, colleagues take leave, and account responsibilities move.

If the useful account history exists mainly in email folders, presentations, spreadsheets, or somebody’s memory, part of it disappears every time the team changes.

A CRM can’t capture every nuance of a human relationship and trying to record everything would make the system way worse rather than better.

A CRM can, however, preserve the parts other people need: HCP and HCO relationships, relevant customer history, tasks, ownership, agreed actions, structured field insight, and changes made over time.

The next person taking responsibility for the account will then inherit an organised customer history instead of a random-looking collection of files and introductions that they have no idea what to do with.

What good pharma key account management looks like in practice

Good pharma key account management gives everyone working the account a shared, current view of priorities, stakeholders, activity, ownership, and next actions.

The underlying principle is fairly simple: not everybody needs to to know everything, but the people responsible for the account need access to the information they need to do their part of the work properly.

Mid-market pharma may not need complex pharma key account management software

Pharma key account management software should match the complexity of the account model it needs to support.

A large global pharmaceutical organisation might need extensive account-plan hierarchies, formal governance processes, specialist workflows, sophisticated stakeholder models, and integrations across many different systems.

But a mid-market pharmaceutical company may be solving a more basic problem.

Its HCPs and HCOs may be stored separately, or affiliations and networks may be difficult to understand. Different colleagues might be working on the same account without enough shared visibility. Tasks may be handled in email, and managers might be using the dreaded spreadsheet to reconstruct what is happening around an organisation.

Adding another layer of process does not help if the underlying customer information is still fragmented.

So, the first requirement is a reliable account foundation.

What pharma key account management software should actually support

Pharma key account management software should connect account structure, HCP and HCO relationships, stakeholder information, shared ownership, field activity, and customer history.

The system must give the team enough connected information to understand and work the account.

That leads to some practical questions for a CRM evaluation.

• Can an HCP be connected to more than one HCO without creating duplicate customer records?
  
• Can a user move from an HCO to the relevant HCPs around it, and from an HCP back to the organisations around them?
  
• Can colleagues see relevant activity already taking place elsewhere in the account?
  
• Can tasks move between users without losing the customer context?
  
• Can account ownership and priorities change when teams or territories change?
  
• Can managers understand what is happening without rebuilding the account manually in Excel?

Those questions get right to the heart of practical KAM support far more quickly than any long feature checklist.

Inception CRM: pharma CRM for key account management that connects the HCP/HCO records

Inception CRM supports practical key account work by connecting HCP and HCO information, customer relationships, field activity, planning, and shared tasks in one system. This is exactly what is needed in modern pharma key account management software.

Its HCP Management capabilities keep customer information connected with the organisational context around the HCP. Inception also supports HCOs as priority customers, workplace information within cycle planning, and customer information that can be updated as field teams learn more.

Its Task Management functionality allows configurable tasks to be assigned between users, with statuses, workflows, comments, and alerts. That provides a structured way to pass customer work between colleagues instead of relying on email, chat threads, or personal reminders.

Field planning sits alongside that customer information. Inception’s Sales Planner helps teams translate customer priorities into coverage and field activity while maintaining visibility into what’s already happened.

A hospital account can change during the cycle

A pharma team begins the cycle with one set of priority HCPs within a hospital. During field activity, the team learns that one specialist has taken on a more important organisational role while another customer has moved elsewhere. A follow-up also needs to be transferred from the KAM to the rep who already owns the strongest relationship with that HCP.

The useful CRM response is not to create another account-planning presentation but to update the customer information, keep ownership clear, assign the action to the right person, and preserve what the team has learned for the next interaction.

This is the level at which Inception supports account-based work: connecting the people, organisations, activity, responsibilities, and customer history that commercial teams need around the account.

HCP information + HCO information + relationships + field activity + shared tasks → connected account knowledge → better coordinated customer work

Account-first KAM in pharma needs account-first customer information

Pharma key account management is moving beyond the idea that a strategic customer relationship can be understood one HCP at a time.

The individual HCP remains important. So does the rep who knows that customer well.

What changes is the context around them.

The usefulness of each customer record therefore depends partly on how well it connects to the wider account.

A CRM does not make a company good at KAM by itself.

It can, however, make good account management much easier by keeping the relevant people, organisations, activity, ownership, and accumulated customer knowledge connected.

For mid-market pharma teams, that may be a more useful starting point than adding another layer of account-management software on top of fragmented customer data.

Are you managing strategic HCP and HCO relationships across territories or with shared employee responsibilities? 

It’s worth having a conversation with us to see how Inception CRM connects customer profiles, organisational relationships, field activity, planning, and shared tasks inside one purpose-built pharma CRM.

Book a demo at a time that suits you or contact us directly at hello@inceptioncrm.com

Christopher Crawford is Head of Marketing at Inception CRM. He writes about the real-world strengths, weaknesses, and trade-offs of CRM, B2B, and B2C software, helping teams make clearer, more informed technology decisions.

FAQ: Pharma key account management

The post Pharma key account management: why account-first KAM needs an account-first CRM appeared first on Inception CRM.

That recommendation might be to follow up on a previous discussion, provide information the HCP asked for, change the timing or focus of the next interaction, or simply wait because there is no good reason to contact the customer again yet.

A modern pharma CRM can hold a lot of information about a customer: their role, organisation, previous visits, content history, event activity, sales or market data, and information from outside healthcare sources. Reps add to that picture every time they speak to an HCP and learn more about their interests, concerns, priorities, or plans.

A CRM can hold all of this information and still leave the rep unsure what to do next.

An HCP might start a sales cycle in one customer segment, based on their profile, interests, and commercial potential but new information captured during field interactions may challenge that classification. A change in attitude, an unresolved objection, or growing interest in another subject might justify moving the HCP into a different segment and adjusting the rep’s tactical approach accordingly.

Next Best Action gives pharma teams a way to adjust as the customer relationship develops by using the latest customer information to help decide which of the available actions makes sense right now.

Next Best Action in pharma at a glance:

A strong Next Best Action in pharma approach should help commercial teams:

• use current HCP and HCO information rather than relying only on fixed plans
• make better use of what reps learn during real customer conversations
• apply clear business rules when the right response is already known
• use AI or predictive analytics where larger patterns can improve the decision
• give reps enough context to understand and judge the recommendation
• recognise that sometimes the right next action is to take no action
• use what happens in interactions to improve later decisions

What does Next Best Action mean in pharma?

Next Best Action in pharma uses available customer information to help decide which commercial action makes sense for an individual HCP at a particular point in time.

That might mean following up on a previous conversation, providing information the HCP asked for, changing the timing of another interaction, focusing on a subject that has become more relevant, or deciding that no further contact is needed yet.

This is a bit different from classic cycle planning. A field plan can set customer priorities, expected call frequencies, territory goals, and the broad pattern of activity for the coming period but new information can come to light after that plan is agreed. New commitments can be made, and activities that are already completed can make another planned call unnecessary.

NBA allows that new information to influence the next commercial decision and supports HCO and HCP management in a way that is far more commercially effective and reality-based.

HCP/HCO information → interaction history → field insight → external customer intelligence → commercial rules and analytics → Next Best Action → field activity → new customer information.

A detailed pharma CRM history can still tell you surprisingly little about the HCP

Pharma CRM systems are very good at collecting activity data, but a history of customer interactions is not the same as a structured understanding of the customer.

A CRM can show when an HCP was visited, which product was discussed, what presentation was used, and which emails were sent. That tells the company what the field team has done, but it doesn’t really explain what the company has learned about the HCP or whether their existing customer classification is still accurate.

Two types of structured information are particularly important for Next Best Action: customer profiles and the responses captured during field interactions.

HCP profiles provide the basis for segmentation. They can include specialty, affiliations, prescribing potential, therapeutic interests, and other relevant characteristics that help commercial teams categorise customers and determine their initial engagement strategy.

Structured call-report answers capture relevant information at a particular point in time, but an HCP may express a new interest, raise an objection, completely change their attitude towards a subject, or request additional information.

Recording these developments consistently helps pharma commercial teams understand how the relationship is changing and determine whether the customer’s profile, segmentation, or next planned activity needs to also change.

Those responses can also challenge the existing customer profile. An HCP previously assigned to one segment may now belong in another, requiring a different level of attention, message, or follow-up strategy.

External healthcare and commercial data can enrich these profiles, while field insight adds information learned directly through the relationship.

Free-text notes remain useful for preserving context, but they are difficult to analyse consistently across a field force. Structured profiles and call-report answers make relevant information far easier to compare, evaluate, and then filter through business rules or predictive analytics.

Without that structure, a CRM can contain years of activity history while still giving an NBA system too little usable information to effectively recommend the most appropriate next action.

Structured HCP insight can change what happens after the rep call

Field reporting doesn’t need to capture every single detail of an HCP conversation but it does need to capture any information that could influence how the customer is understood and what should happen next.

A pharma company can identify the customer signals that matter to its commercial strategy and build them into structured call reporting. Things like unresolved objections, changing interest in a therapeutic subject, requests for additional information, or commitments agreed during a visit.

Question cadences should also reflect the conversation. A rep who records an unresolved objection may need to provide more detail about it, while a rep who records a new area of interest may need to capture a totally different set of information.

This allows the company to gather consistent, relevant insight without forcing every rep to complete the same lengthy questionnaire after every interaction. The resulting answers can then properly update or enrich the HCP profile, contribute to customer segmentation, and help determine the next appropriate commercial action.

The rep still decides how to conduct the meeting while the company decides which aspects of what the rep learned are useful enough to capture in a structured form.

When similar information is recorded across the field force, it becomes easier to uniformly analyse HCP responses, identify changes in HCP behaviour, reassess segmentation, and apply consistent commercial rules.

This is also why Next Best Action can’t depend entirely on external customer data… because some of the strongest data insights only emerge through the human-to-human relationship itself.

Inception CRM supports this approach through dynamic, interactive questionnaires within field reporting. Its Sales Planning functionality uses skip logic to adapt questions according to previous answers, helping reps capture relevant information without completing unnecessary fields.

Those structured responses can be linked to HCP and HCO profiles, making field insight available for customer analysis, segmentation, and subsequent commercial decisions.

Activity reporting: customer visited → product discussed → activity completed

Structured customer insight: customer visited → relevant HCP response captured → profile updated → information available for the next decision

Rules and AI solve different problems in pharma Next Best Action

AI has expanded what NBA in pharma can do, especially when commercial teams need to identify patterns across large combinations of customer signals but more sophisticated technology doesn’t automatically produce better recommendations. 

The right approach depends on the decision being made and the information available.

Machine-learning models can find links across interaction histories, customer attributes, digital behaviour, timing, channels, and later outcomes that would be difficult to spot through ordinary analysis.

There are also plenty of situations where the company already knows what the rule should be. An HCP may have asked for a particular follow-up, an activity may become due after a certain event, or another action completed recently may mean the proposed next activity is just no longer needed.

There’s no point in asking a predictive model to rediscover something the company has already decided.

Deterministic business logic works well in these cases because the rules are clear. The company can set the conditions, see why they lead to a particular recommendation, and then change them when the sales strategy changes.

AI and predictive analytics are much more useful when the answer is less obvious and little more complicated. They can more easily and quickly spot when historical data shows that certain combinations of behaviour, customer characteristics, timing, or previous interactions are strongly linked to a better chance of a useful customer response.

Compare deterministic logic in pharma CRM vs. AI and predictive analytics

Known commercial condition → deterministic business logic
Complex historical patterns → predictive analytics and AI
Both contribute to the recommendation shown in the CRM

The recommendation has to make sense to pharma field reps

An NBA model can work well on paper and still have no effect on day-to-day sales activity if the recommendation is hard for a rep to understand.

A message simply telling the rep to contact an HCP is much less useful than one that also shows the rep why this decision was made. If the previous visit recorded an unresolved question and an agreed follow-up, showing the rep that context makes it much easier for the rep to judge whether the recommendation still makes sense.

Field judgement still matters enormously because CRM information is never perfectly up to date. Another colleague may already have dealt with the issue, circumstances may have changed, or the rep may know just from the relationship they have with thr HCP that the timing is poor or the planned interaction makes no sense at all in reality.

NBA therefore works better inside the normal CRM workflow than as a separate analytical output.

The rep should not have to piece the reasoning together from several dashboards and earlier call reports.

And if reps repeatedly ignore recommendations or change them, that’s also a sign that things are going badly off course.

Sometimes the correct Next Best Action is to do nothing

Commercial CRM data tends to favour activity that can be seen and counted, for example, calls are counted, visits are measured against the plan, and emails and content interactions are all recorded.

That doesn’t mean every HCP needs another interaction simply because the system can recommend one.

An HCP may have been contacted recently, already received the relevant information, or have no outstanding issue that needs another discussion. An agreed follow-up may still be several weeks away.

This matters when field resources are limited. An unnecessary interaction with one HCP also takes time away from another, potentially more valuable, interaction or one that has more sure commercial outcomes.

A mature pharma Next Best Action approach needs to recognise when waiting makes more sense. Low activity with one HCP is not automatically a problem if that HCP has already received the right level of attention and there’s currently no good reason to contact them again.

NBA becomes more useful when HCP/HCO knowledge keeps changing with the relationship

The first recommendation made for an HCP is based on what the company knows at that moment, but the next interaction could create a completely new and commercially-valuable insight.

A customer may respond differently from expected, a question may expose a gap in the existing profile, a rep may discover that an assumption about the account is complete nonsense, or that a subject that seemed minor matters much more to the HCP than anyone expected.

Recording those outcomes makes the customer profile way more useful over time.

Inception CRM’s integrations with external healthcare-data providers offer a practical example.

Licensed third-party information can be brought together within individual HCP and HCO profiles, alongside first-party commercial knowledge gathered through visits, emails, CLM activity, and other customer interactions.

Inception can then apply client-specific deterministic business rules to this combined information to support sales decisions and Next Best Action recommendations.

Healthcare intelligence in a separate reporting platform can still be useful for analysis, but bringing relevant customer information into the CRM also makes it available where the customer is being planned, visited, reported, and reviewed and also allows for far more holistic and connected analysis.

Over time, the customer record reflects both outside data and what the company has learned through its own relationship with the HCP.

Customer information → commercial decision → field interaction → new HCP insight → updated customer profile → revised recommendation → next interaction

Next Best Action software needs to work beyond the demo

NBA demonstrations naturally focus on the recommendation itself. The customer is selected, several signals or insights are analysed, and the system produces what looks like an intelligent next step.

Pharma companies need to pay close attention to that recommendation as well.

The source information matters first. If the recommendation is based on old or fragmented data, or misses what the field team has recently learned, even a sophisticated model has an incomplete picture and can deliver an NBA that damages the company.

Commercial teams also need to know how easily the rules can change.

Brand strategies evolve, teams enter new markets, customer classifications are revised, and priorities shift during the product lifecycle. Recommendations must also respect applicable consent requirements, approved content, customer engagement restrictions, and company compliance policies.

If every commercial or compliance change requires substantial redevelopment, the system very quickly becomes harder to manage.

The recommendation should also appear where the rep already works. If users have to leave the CRM, open another analytics system, interpret a score, and then create the activity manually, much of the advantage disappears.

Do not make your reps flick between hundreds of screens or apps.

Managers should be able to see what was recommended and how the field team responded, too. Repeated patterns can show that a rule, customer profile, or piece of source data need to be reconsidered before any concrete action is taken.

These everyday details often decide whether Next Best Action in pharma sales becomes part of normal field work or remains something teams hate, do not respect and only grudgingly check occasionally.

Inception CRM uses deterministic logic to keep client-specific NBA rules under control

Inception CRM’s current Next Best Action approach uses deterministic business logic applied to customer information held inside the CRM.

The platform can combine HCP and HCO profiles, commercial interaction history, structured field insight, and relevant external customer intelligence. The client then sets the rules that determine how this information should influence the next action.

A particular customer response may require a defined follow-up. A change in an HCP’s profile or segment may call for a different tactical approach. A recent interaction may mean another recommendation should not appear yet.

These rules reflect the client’s own segmentation model, commercial priorities, and sales strategy rather than forcing every company into the same generic approach.

Structured field reporting adds more useful information to those decisions. Inception’s dynamic questionnaires use skip logic to keep the questions relevant to the answers being recorded and connect the resulting insight to customer profiles.

For mid-market pharma companies, effective NBA really doesn’t have to begin with predictive AI. Where the appropriate commercial response is already understood, deterministic business rules provide a clear, controllable way to turn customer intelligence into action. Predictive analytics adds value when the decision requires pattern recognition that defined rules simply cannot provide.

HCP/HCO information + external customer intelligence + structured field insight → consolidated customer profile → client-specific deterministic logic → Next Best Action → rep decision → new customer knowledge

Predictive analytics can be added where extra pattern recognition improves the decision.

Better Next Best Action starts with understanding the customer well enough to act

AI allows pharma commercial teams to analyse more customer information and find patterns that would previously have been difficult to see.

A useful recommendation still has to make sense for the HCP as they are now, fit the company’s sales strategy, and reach the rep in a form they can actually use.

Sometimes that will involve predictive analysis and sometimes the right action follows directly from something the HCP said and a business rule the company already has. Often both will play a part.

If this makes sense to you and your business needs, then book a demo of our CRM or write to us via our email address: hello@inceptioncrm.com to see how Inception CRM turns HCP and HCO intelligence into valuable, practical commercial guidance that leads to concrete commercial outcomes.

Explore structured field reporting, customer-level healthcare data, and configurable business logic designed to help your teams make better decisions inside the CRM.

FAQ: Next Best Action in pharma

Christopher Crawford is Head of Marketing at Inception CRM. He writes about the real-world strengths, weaknesses, and trade-offs of CRM, B2B, and B2C software, helping teams make clearer, more informed technology decisions.

The post Next Best Action in pharma CRM: what commercial teams need from NBA appeared first on Inception CRM.

For example, a pharma company might start in Taiwan, add regional oversight from Singapore, work through local partners in Vietnam or Malaysia, and then expand into markets such as Thailand, Indonesia, the Philippines, or Hong Kong. Each step adds commercial opportunity, but also another layer of local healthcare structures, privacy requirements, promotional rules, account relationships, and field processes.

That’s where the design of pharma CRM across Asia starts to really matter.

Regional management still needs one coherent view of HCPs, HCOs, activity, and performance, while local teams need a system that reflects the market they actually work in.

A good multi-country pharma CRM has to do both: create regional consistency where consistency is useful, without flattening the local differences that shape how pharmaceutical companies sell, engage HCPs, and manage accounts across Asia Pacific.

Pharma CRM requirements across Asia Pacific

These aren’t cosmetic differences. They affect how commercial teams work in day-to-day real life.

Pharma CRM in Southeast Asia: Regional consistency has to leave room for local reality

ASEAN has spent years bringing pharmaceutical regulation closer together. The ASEAN Pharmaceutical Regulatory Policy and Pharmaceutical Regulatory Framework provide a common direction for member states and are intended to improve regulatory cooperation and harmonisation.

National legislation still matters, however, and the ASEAN framework explicitly operates alongside national regulatory systems. Taiwan and Hong Kong aren’t part of that ASEAN framework in the first place.

That distinction becomes important as soon as a CRM moves beyond a single-country deployment.

It is particularly relevant when deploying pharma CRM in Southeast Asia, where neighbouring markets can still differ materially in healthcare structures, privacy requirements, commercial models, and routes to market.

A regional commercial director may reasonably want the same definition of a call, activity, customer segment, or territory across the business, with dashboards that make performance in Singapore comparable with performance in Thailand or Vietnam.

The local affiliate still needs to work within its own healthcare system, privacy rules, promotional controls, account structures, and route to market.

The answer isn’t to treat every market as a separate technology project — instead, it’s crucial to decide what should be common across the organisation, then configure what genuinely needs to remain local.

APAC cross-border HCP data needs more care than a single regional privacy setting

HCP and HCO data offers one of the clearest examples of the tailored approach pharma companies in Asia need to take across markets.

Singapore’s Personal Data Protection Act includes a Transfer Limitation Obligation for personal data sent outside Singapore, with requirements intended to maintain a comparable standard of protection. Malaysia issued specific cross-border personal-data transfer guidelines in 2025, while Taiwan’s Personal Data Protection Act allows its competent authorities to restrict overseas transfers in defined circumstances.

Vietnam has changed particularly recently. Its new Law on Personal Data Protection, Law No. 91/2025/QH15, came into force on 1 January 2026, with Decree 356/2025/NĐ-CP taking effect on the same date. For regional CRM deployments, that matters because transferring or processing Vietnamese personal data outside the country can trigger cross-border transfer assessment and documentation requirements.

Hong Kong adds another consideration around direct marketing. Organisations using personal data for direct marketing generally need to provide prescribed information and obtain consent or an explicit indication of no objection, rather than treating silence as permission.

There isn’t one sensible button marked APAC privacy that solves all of this.

For pharma CRM teams, the practical requirement is the ability to manage permissions, communication preferences, consent where applicable, access controls, retention policies, and audit history without breaking the regional customer record into disconnected systems.

It also means being precise about what data is being discussed. A commercial pharma CRM predominantly handles information about HCPs, HCOs, accounts, interactions, activities, and commercial relationships; that shouldn’t be confused with systems processing patient medical records.

Approved content and digital engagement have to respect distinct Asian market legislation

Pharma commercial teams in the region also work under specific controls on medicine promotion.

Singapore’s Health Sciences Authority prohibits prescription-only medicine advertising to the public, while allowing it in defined professional contexts, including material distributed to relevant healthcare professionals. Its definition of advertising covers internet channels, social media, and electronic direct mail, as well as traditional media.

Taiwan’s IRPMA Code, which applies to member companies, covers pharmaceutical promotion and interactions with healthcare professionals across communication methods including the internet.

Indonesia has moved recently too. BPOM Regulation No. 7 of 2026 now governs drug promotion and advertising, replacing BPOM Regulation No. 2 of 2021, and expressly recognises restricted digital promotion and e-detailing for medical and healthcare professionals.

For pharma commercial operations, this pushes content control much closer to the CRM.

A rep shouldn’t have to remember which presentation, indication, email template, or version is appropriate every time they open an HCP record. The platform should make the correct approved material easy to use and the wrong material difficult to use, with the resulting interaction recorded.

That is where pharma CLM, Approved Email, DAM, and MLR workflows become useful operational controls rather than a list of software features.

Asian pharmaceutical distributor relationships have to be visible, not kept outside the CRM

One of the easiest mistakes in regional CRM design is to assume the customer relationship always runs directly from the pharmaceutical company to its own field force and then to the HCP.

Across these markets, local agents, distributors, and other partners can sit directly inside the commercial model.

A Southeast Asia pharma CRM therefore needs to accommodate both direct field teams and partner-led commercial models without fragmenting regional customer data.

Malaysia is a good example. Local distributors are widely used for market entry, while foreign companies competing for Malaysian government procurement often need local participation; government procurement can also favour Bumiputra suppliers.

This changes what a regional CRM has to represent.

The company may have its own employees in Taiwan, regional management in Singapore, and distributor-led teams elsewhere. Those users shouldn’t necessarily have the same permissions, but the company still needs control over customer ownership, activity history, territory information, and reporting.

Keeping distributor activity in spreadsheets or in a completely separate system may be convenient locally, but it weakens regional visibility precisely when the business begins to scale.

In Asia, public healthcare structures change the shape of the customer

In a generic CRM, an account can often be reduced to a company and a set of contacts. Pharma needs a richer picture, particularly where reimbursement, hospital structures, and public procurement shape access.

Taiwan’s National Health Insurance Administration, or NHIA, determines whether newly approved medicines are listed for reimbursement and sets the reimbursement price for products that are accepted.

Thailand operates three main public healthcare schemes: the civil-service welfare system, social security, and the Universal Coverage Scheme.

Indonesia’s national healthcare framework brings another model. Under JKN/BPJS Kesehatan, medicines can be procured through national tenders, hospital tenders, and the national e-Katalog/e-purchasing system.

Hong Kong is different again. The Hospital Authority manages 43 public hospitals as well as specialist and general outpatient clinics, and is the largest pharmaceutical end-user in the territory.

That is why HCO management matters as much as HCP management in a regional pharma CRM.

A hospital shouldn’t simply appear as an address attached to a doctor. Commercial teams may need to understand the hospital group, department, payer or reimbursement context, procurement relationship, and the HCPs connected to that organisation.

The exact hierarchy will differ by country, which is another reason local configuration matters.

Asian pharma field environments aren’t uniform either

Indonesia stretches across more than 17,000 islands, while commercial teams in the Philippines may cover Metro Manila alongside provincial markets in Luzon, Visayas, and Mindanao. Philippine healthcare digitisation is also uneven: larger private hospitals have adopted electronic systems, while smaller rural facilities may still depend heavily on paper and some provinces continue to face connectivity challenges.

A regional CRM buyer therefore needs to look beyond the desktop demo.

Can a rep move quickly between customer records, calls, tasks, and content on a phone or tablet? Does the system remain usable when connectivity is poor? How much administration is required after each interaction? Can managers change territories without turning the exercise into an IT project?

These sound like ordinary usability questions, but they become more important when a system has to work for teams spread across countries, cities, islands, and very different commercial environments.

Pharma CRM in Singapore

Pharma CRM in Singapore deserves particular attention because its role is larger than its domestic market suggests.

The Singapore Economic Development Board reports more than 80 regional headquarters in its biomedical sciences ecosystem, alongside 60 manufacturing plants and 30 R&D centres.

For an APAC pharma CRM project, that can make Singapore the place where regional governance lives even when most users are elsewhere.

For companies evaluating pharma CRM in Singapore, that means looking beyond the needs of the domestic sales team and asking whether the platform can support regional operations as well.

An APAC pharma commercial operations team based in Singapore might need dashboards covering six markets, while local teams need their own territory plans, content, account classifications, and reporting views. A Singapore pharma CRM deployment that works well locally but becomes cumbersome as affiliates are added hasn’t solved the real requirement.

This is also where reporting design matters. Regional KPIs should be consistent enough to compare, but consistency shouldn’t mean forcing every local team into workflow steps that exist only to make the dashboard tidy.

Pharma CRM for Taiwan presents a different starting point for pharma companies

Taiwan combines a sophisticated healthcare system with centralised NHI reimbursement and a strong domestic biotechnology and pharmaceutical sector.

For companies evaluating pharma CRM for Taiwan, the question often changes quickly from what does our local sales team need? to what can we take with us into the next market?

That makes architecture important early. A Taiwan pharma CRM deployment may need to support regional expansion much sooner than a purely domestic implementation.

HCP and HCO data, activities, approved content, and reporting should be structured well enough to scale, while country-specific rules remain configurable rather than being buried in custom code.

The same principle applies in the other direction. A company operating regionally shouldn’t have to force a Taiwanese team into a process designed around the commercial structure of another country simply because Taiwan was added later.

Vietnamese pharma is growing quickly, while the operating environment is still evolving

Vietnam’s pharmaceutical market was worth approximately $6.4 billion in 2024 and is forecast to reach about $9.4 billion by 2029, according to BMI figures cited by the U.S. Commercial Service. The same source points to substantial rural/urban differences in healthcare capacity.

Add the new personal-data regime that took effect in 2026 and the argument for configurable regional systems becomes fairly practical: the system has to accommodate change without requiring the regional organisation to redesign its CRM whenever legislation, internal governance, or local operating processes move.

Malaysian healthcare needs public/private context as well as local commercial relationships

Malaysia’s healthcare system has a clear public/private dimension. Private providers have been prominent in health technology adoption and medical tourism, while public providers remain central to national access and healthcare capacity.

Government procurement brings local-partner considerations into the commercial model too.

There is even a locally specific product consideration that rarely appears in European CRM discussions: Malaysia has a voluntary halal pharmaceutical certification framework, and certified products can receive commercial preference in relevant contexts.

The point isn’t that a CRM needs a special “Malaysia mode” — but that it needs a data model flexible enough to carry the local product, account, and market attributes that matter without losing the common regional structure.

What should actually stay common across Asian pharma country markets?

This table illustrates a useful dividing line between what needs to be kept regionally consistent and what can be configures locally.

This is a better starting point than either extreme.

Separate CRMs for every affiliate make consolidated reporting, governance, and customer-data quality unnecessarily difficult. A rigid regional template can be just as damaging if country teams spend their working day bypassing processes that don’t reflect their market.

The objective is controlled local variation.

Pharma CRM customer care is crucial, especially if the vendor is based in the EU

Software capability is only part of the buying decision for an APAC pharma CRM rollout, particularly when the CRM vendor is based in Europe and users are spread across several markets.

The implementation team has to understand which requirements genuinely need local configuration and which ones should remain part of the regional standard. Someone also has to support data migration, train administrators and field teams, help onboard later affiliates, respond when something breaks, and stay involved once the launch project is over.

Distance makes poor support more visible.

It doesn’t make a European vendor a poor choice, though. A European pharma specialist can bring experience shaped by stringent data-governance and life-sciences compliance expectations, while giving Asian affiliates a platform that isn’t tied to one national market. The real test is whether the vendor combines that discipline with responsive service and a willingness to adapt the implementation around the customer’s local operations.

That distinction is important. A technically strong system with remote, ticket-only customer support can become frustrating very quickly when several markets are being brought online. A vendor that stays close to the implementation can make the geographic distance largely irrelevant.

What a regional pharma CRM should be able to handle

Why Inception CRM fits multi-country Asian pharma teams

Inception CRM was built for mid-market pharmaceutical companies that need pharma-specific depth without turning the CRM itself into a major enterprise transformation programme.

That distinction becomes useful in APAC pharma CRM deployments, where complexity should come from the markets the company serves, not from the software used to manage them.

Most Inception CRM implementations take 4–12 weeks, with the implementation scope able to account for the number of countries and affiliates, data migration, integrations, and module requirements. Full data migration support is included as standard. This makes Inception CRM a top choice for Asian pharmaceutical companies.

The platform brings HCP/HCO management, CLM, Approved Email, MLR workflows, activities, events, analytics, and other core pharma functions into the same environment, allowing commercial teams to establish a common regional foundation while configuring local workflows where they are genuinely needed.

Support is equally important for companies working several time zones away from Europe. Every Inception CRM licence includes standard support, while customers receive a dedicated account manager and can reach the team through phone, email, WhatsApp, Microsoft Teams, or the ticketing system. Critical issues have free 24/7/365 on-demand assistance, and companies needing more operational help can add support for administration, data imports, custom reporting, dashboards, and system consultation.

That matters when Taiwan is the first market rather than the last, or when a Singapore regional team knows that Vietnam, Thailand, and Indonesia are next.

You don’t need to design the entire future rollout on day one. You do need a CRM and a vendor that won’t make each additional country feel like starting again.

Build the regional model once, then let each Asian market work as it must

The attraction of a regional CRM is consistency, but consistency is useful only where the underlying business is actually consistent.

Taiwan’s NHIA reimbursement system isn’t Indonesia’s e-Katalog. A Singapore regional office doesn’t operate like a distributor field force in another market. Hong Kong’s Hospital Authority produces a very different account landscape from the Philippines’ spread of public, private, and provincial healthcare facilities.

Those differences aren’t implementation problems to be ironed out, that’s just the reality of the markets you’ll be serving.

The more clever CRM strategy is to preserve regional differences where they matter, while keeping the customer data, governance, commercial visibility, and technology underneath that totally connected.

For pharmaceutical companies expanding across Asia, that gives local teams room to work the way their market requires, while regional management still gets the coherent commercial picture it needs.

Planning a multi-country pharma CRM rollout in Asia? See how Inception CRM can support regional commercial operations with country-level flexibility, fast implementation, and hands-on support from rollout through ongoing operation.

Christopher Crawford is Head of Marketing at Inception CRM. He writes about the real-world strengths, weaknesses, and trade-offs of CRM, B2B, and B2C software, helping teams make clearer, more informed technology decisions.

The post Pharma CRM in Asia Pacific: what multi-country deployments really require appeared first on Inception CRM.

Release notes: Inception CRM 2026.3 for iOS helps field teams use their time more effectively by showing how far away customers are, displaying institution addresses directly in Search, and reducing repeated data entry when placing repeat orders.

The release also brings Apple’s new Liquid Glass design to the app, alongside bug fixes, improvements, and optimizations.

A new look built for iOS 26

Inception CRM 2026.3 adopts Apple’s new Liquid Glass design across the iOS app.

Users on iOS and iPadOS 26 will see an updated visual design, navigation, and controls that are more consistent with Apple’s own system apps.

The result is a more familiar, native-feeling experience for reps already working on the latest version of iOS.

Find nearby customers faster

Field teams often need to adjust plans during the day. If a meeting ends early or a rep has time between visits, the key question is simple: which customers are nearby?

The Search list now shows how far away each customer is from the rep’s current GPS position.

This makes it easier to spot nearby customers, plan unscheduled visits, and reorganize the day without opening individual records one by one.

Distances are shown when location access is enabled for the app.

Identify the right institution at a glance

Pharmacy chains and other institutions can have several locations with similar or identical names. Without the address visible, reps may need to open several records before finding the right one.

The Search list can now show an institution’s address directly in the list, on the second, third, or fourth line of the row depending on your company’s configuration.

Combined with the new distance information, reps can now see which institution they are looking at, where it is, and how far away it is before opening the record.

Place repeat orders with way less data entry

Pharmacies often reorder using many of the same details as their previous order. Re-entering that information every time slows reps down and creates more opportunities for mistakes.

Administrators can now configure Inception CRM to pre-fill the header of a new order using data from the last order placed for that pharmacy.

When a rep starts a new order and selects the pharmacy, the relevant header information is filled in automatically. The rep can then add the required order lines as usual.

This reduces repetitive data entry and helps reps create repeat orders faster and more accurately.

The post Inception CRM 2026.3 for iOS adds faster search, easier ordering, and a new design for iOS 26 and higher appeared first on Inception CRM.

The RFP should also require vendors to explain how each requirement will be delivered. A capability might be standard, configurable, dependent on custom development or third-party software, planned for a future release, or unavailable. Several vendors can answer “yes” to the same requirement while proposing very different costs, timelines, and levels of complexity.

If you are still defining the broader requirements for a new platform, our guide to choosing a pharma CRM covers that earlier stage of the process.

What should a pharma CRM RFP include?

A pharma CRM RFP should cover the requirements that affect customer data, field execution, compliance, implementation, user adoption, support, and the long-term cost of running the system.

Pharma CRM RFP evaluation areas

The RFP should make vendors respond to the same important requirements in enough detail for commercial, IT, procurement, and field stakeholders to compare them properly.

RFI vs. RFP: which should you use when buying a pharma CRM?

Use an RFI when you are still exploring the market and need to understand which vendors could meet your needs. Use an RFP when your main requirements are already defined and you are ready to compare suitable vendors in detail.

RFI vs RFP for pharma CRM selection

An RFI can make sense when you are replacing a complex existing CRM, entering new markets, or dealing with integrations and local requirements that make the available options unclear. If your requirements and likely vendors are already well understood, moving directly to an RFP may be more efficient.

What makes a pharma CRM RFP different from a generic CRM RFP?

A pharma CRM RFP needs to test workflows, data structures, and controls that a generic CRM evaluation may never address. Managing an HCP relationship, compliant field interaction, approved content, sample activity, or multi-country pharma operation is different from managing a standard B2B sales pipeline.

Generic CRM RFP vs pharma CRM RFP

A generic feature checklist can produce responses that look more similar than the products really are. Several CRMs may manage contacts, activities, email, and reporting while handling the pharma workflows behind those features in very different ways.

For a fuller explanation of those specialist requirements, see what a pharma CRM is and how it differs from a generic CRM.

How should pharma CRM vendors answer RFP requirements?

Pharma CRM vendors should state how every important requirement will be delivered, rather than giving a simple yes or no.

How to classify pharma CRM vendor responses

For important requirements, ask vendors to add the expected implementation work, any additional licence or services cost, who is responsible for delivery, and evidence that the capability works as described.

The evidence might be a live demonstration, product documentation, an existing customer implementation, or a reference call, but the response should show that the capability works as described.

25 questions to include in a pharma CRM RFP

These pharma CRM RFP vendor questions are designed to find out how the system will work in practice, what has to be configured or built, who is responsible for delivering it, and what it will cost.

HCP and HCO data and targeting

1. How does the CRM manage HCPs with multiple workplaces and affiliations?

Ask the vendor to demonstrate how one HCP can be linked to several practices, hospitals, groups, or other HCOs without creating fragmented customer records. The answer should also show how affiliation changes are managed over time.

2. How are HCPs, HCOs, and account hierarchies connected?

The CRM should give users a clear view of the relationships between individual healthcare professionals and the organisations around them. Ask the vendor to show the structure rather than simply confirming that account hierarchies are supported.

3. How does the CRM support HCP targeting and segmentation?

Find out how targeting criteria, segments, priorities, and field activity are connected, and how easily those priorities can be changed when commercial plans change.

4. Who owns the customer data stored in the CRM?

The response should make data ownership, export rights, and access at the end of the contract clear. Ask what format the data can be exported in and whether additional fees or professional services are required.

Field workflows and rep adoption

5. How does a rep plan, record, and follow up an HCP interaction?

Ask the vendor to demonstrate the complete workflow, rather than showing three separate features. Pay attention to the number of steps, required fields, duplicate entry, and how much work remains after the interaction.

6. What can field users do from mobile devices?

The vendor should identify which common activities can be completed on mobile and which still require desktop access. If offline working matters in your markets, make it an explicit requirement.

7. How much training does a new field user normally require?

Ask for the normal onboarding approach, the training expected for a standard rep, and what additional training is needed for managers and administrators.

Usability deserves close attention because adoption problems usually appear after the rollout, when reps are under normal field pressure. Our article on why pharma CRM adoption fails looks at that problem in more detail.

8. Which parts of the field workflow can be configured?

Find out which fields, screens, stages, and rules can be changed without development work. A workflow that suits one sales organisation perfectly may create unnecessary admin for another.

Compliance, consent, and approved content

9. How are HCP consent and communication preferences managed?

Ask how consent is recorded, updated, viewed, and applied across relevant communication channels, and how the system handles different requirements between markets.

10. What audit history does the CRM provide?

The vendor should explain which actions and record changes are logged, how long that information is retained, and who can view or export it.

11. How does the CRM control approved content?

Ask how teams publish approved materials, manage versions and expiry dates, restrict access where necessary, and prevent outdated content from remaining available in normal field workflows.

12. How are CLM and Approved Email connected to the HCP record?

Ask how content use and engagement become part of the customer history and what managers can analyse afterwards.

Territory, cycle planning, and analytics

13. How does the CRM support territory and cycle planning?

Ask vendors to demonstrate how targets, territories, cycle objectives, visit frequency, and rep capacity become practical plans for field teams.

14. Can managers compare planned activity with actual execution?

The vendor should show whether managers can see if priority HCPs are being reached at the required frequency without building the analysis manually outside the CRM.

15. How are HCP coverage and visit frequency reported?

Ask the vendor to define how these metrics are calculated and demonstrate how a manager would review them by rep, territory, segment, or cycle.

16. Can managers change priorities after a cycle has started?

Commercial priorities change, so ask how easily teams can adjust targeting, required visit frequency, territories, or cycle objectives once a plan is active.

Integrations, architecture, and migration

17. Which CRM integrations are standard, configurable, or custom?

List the systems that genuinely matter to your operation. Require the vendor to state whether each connection is native, configurable, API-based, custom-built, or dependent on another provider.

18. Who builds and maintains each CRM integration?

An integration can be technically possible while creating a long-term dependency on consultants or third parties. Establish who delivers it, who supports it, and what happens when either connected system changes.

19. What exactly is included in CRM data migration?

Ask vendors to define which objects, historical activities, attachments, relationships, consent records, and other data will move to the new platform.

Migration scope has a direct effect on implementation effort, so it is worth defining early. Our guide to pharma CRM data migration explains what the process normally involves.

20. How will migrated CRM data be validated before go-live?

The migration plan should explain how data quality will be checked, who signs off the result, and how missing or incorrectly mapped information will be resolved.

Multi-country rollout, implementation, and support

21. What can be standardised centrally and configured locally?

Ask the vendor to demonstrate how corporate teams can maintain visibility and common standards while allowing local markets to manage legitimate differences.

22. Who is responsible for each part of CRM implementation?

Separate vendor work, internal work, and work carried out by implementation partners. The response should identify dependencies that could delay delivery or create additional cost.

The implementation model matters because complexity grows quickly when every possible exception is included from the start. See our guide to implementing pharma CRM for a deeper look at rollout planning.

23. What CRM support is included after go-live?

Ask about support channels, response expectations, escalation, included services, customer success support, and anything that requires an additional contract.

Support deserves close attention because weak support can quickly turn a technically capable CRM into an operational problem. Buyers should understand who will answer questions, how quickly important issues will be handled, which services are included, and what happens when a problem needs specialist help.

Pricing, contract terms, and exit

24. What is the total cost of the pharma CRM over the proposed contract period?

Require separate figures for licences, implementation, migration, integrations, support, training, additional modules, and mandatory third-party services. A low licence price means little if necessary capabilities appear later as paid extras.

Our guide to pharma CRM pricing explains why licence cost alone gives an incomplete picture of the total cost of ownership.

25. What happens to our data if we leave the CRM?

Ask how data is exported, what assistance is provided, whether exit charges apply, and how long access remains available after termination. These conditions are much easier to establish before a contract is signed.

Weak vs strong pharma CRM RFP questions

Broad RFP questions make broad answers possible. More specific questions reveal how the software will work, what has to be delivered, and what the commercial consequences will be.

Examples of stronger pharma CRM RFP questions

How should you compare pharma CRM vendor demos?

Ask every shortlisted vendor to complete the same real workflows using scenarios that resemble your own operation. This makes it easier to compare how each CRM handles the work your teams will actually perform.

A useful demonstration could require the vendor to:

• find an HCP with multiple affiliations,
• plan and record a field interaction,
• use approved CLM content and capture engagement,
• update an HCP communication preference,
• change a cycle plan after rep availability changes, and
• show the resulting activity from a manager’s view.

A vendor-led demo will naturally focus on the product’s strongest features. Standardised workflows give you a more useful comparison of usability, configuration, and the amount of effort required to complete everyday tasks.

How should pharma CRM vendors be scored?

Start with genuine pass/fail requirements, then use weighted scoring where trade-offs are acceptable. A vendor should not compensate for failing a mandatory requirement simply by scoring well in less important areas.

A necessary integration, data-residency condition, or other non-negotiable requirement may therefore need to act as a gate before weighted scoring begins.

For everything else, an evaluation model like this can provide a starting point. The weightings are illustrative and should be adjusted to match your priorities.

Example pharma CRM vendor scoring weights

Set the weightings before the proposals are scored. Changing them after seeing the responses makes it easier for an existing preference for one vendor to influence the result.

These weights are illustrative and should reflect your own priorities. Mandatory compliance, data, integration, or market requirements should be treated as pass/fail criteria rather than traded off against higher scores elsewhere.

What are the biggest red flags in a pharma CRM RFP response?

The biggest warning signs are responses that hide extra complexity, cost, or delivery risk behind a simple claim that a requirement is supported.

Look more closely when:

• core requirements repeatedly depend on custom development,
• important functionality is only on the product roadmap,
• migration ownership is unclear,
• required third-party products are missing from the commercial proposal,
• the vendor cannot demonstrate important field workflows,
• implementation or support costs remain undefined, or
• data extraction at the end of the contract is difficult or expensive.

Any of these can change the real cost or risk of the project, so they should be understood before scoring is complete. A strong pharma CRM request for proposal makes these potential concerns visible before vendors reach the shortlist.

How should you compare standard, configurable, custom, and third-party CRM capabilities?

Compare them according to the work, cost, ownership, and long-term maintenance needed to make the requirement function in practice. Two vendors can both say that they support a capability while proposing very different ways of delivering it.

Cycle planning shows why this distinction matters. One CRM may provide it as standard functionality that an administrator can configure. Another may meet the same requirement through a separate planning product, professional services, and an integration.

Both vendors can truthfully answer “yes” to “Do you support cycle planning?”, while the implementation effort, cost, support model, and long-term maintenance can differ substantially.

Recording how each important requirement is delivered prevents feature availability from becoming a misleading binary comparison.

What should happen after pharma CRM RFP responses come back?

Once responses have been checked against mandatory requirements and scored, use clarification questions to resolve any remaining ambiguity before creating the shortlist. Shortlisted vendors should then complete the same workflow-based demonstration, with reference checks or a pilot added where the scale or complexity of the project justifies them.

Commercial comparison should use the same scope for every vendor. If one proposal includes migration and support while another does not, the headline totals cannot be compared fairly.

The final evaluation should reflect what each vendor can deliver, how it will be delivered, what internal work it creates, and what the full commercial commitment looks like.

How many vendors should you include in a pharma CRM RFP?

There is no fixed number that works for every project. The shortlist should be large enough to give you a meaningful comparison, but small enough that your team can assess each response and demonstration properly. An RFI can help reduce a larger market to a manageable RFP shortlist.

Should you issue an RFI before a pharma CRM RFP?

An RFI is useful when you are unsure which vendors can meet your main requirements or when you need to understand the available approaches before defining the RFP. If your requirements and likely vendors are already clear, another procurement stage may add little value.

Should CRM vendors provide implementation pricing in the RFP?

Yes, when the implementation scope is defined well enough for the figures to mean something. Vendors should separate implementation from software licences and state their assumptions, excluded work, third-party dependencies, and services that could change the final cost.

Should pharma companies run a CRM pilot before signing a contract?

A pilot can be useful when adoption, configuration, integrations, or an important workflow still needs to be proven, but it is not necessary for every CRM purchase. If you run one, define what the pilot needs to prove and how success will be judged before it begins.

From pharma CRM RFP to final vendor selection

A well-built pharma CRM RFP gives every vendor the same opportunity to show what they can actually deliver. Once the responses, demonstrations, pricing, implementation assumptions, and support models are compared side by side, the differences should be clear enough to make a defensible shortlist and final decision.

Keep the final evaluation tied to real workflows and real delivery. Require vendors to show how important requirements work, identify what is standard, configurable, custom, or third-party, and put implementation, support, and additional costs on the table. Hidden complexity is much easier to identify before the contract is signed than after the project has started.

For pharma companies, CRM becomes part of day-to-day field operations, so the RFP should leave you with a clear view of what each vendor can support, what implementation will involve, how much help you can expect after go-live, and what the full commercial commitment will be.

Christopher Crawford is Head of Marketing at Inception CRM. He writes about the real-world strengths, weaknesses, and trade-offs of CRM and B2B software, helping teams make clearer, more informed technology decisions.

FAQ: Guide to pharma CRM RFP

The post Pharma CRM RFP: Questions to ask pharma CRM vendors before you make a shortlist appeared first on Inception CRM.

Healthcare data can support customer targeting, segmentation, territory planning, field execution and commercial analysis, but having access to healthcare data doesn’t automatically make it usable by pharma commercial teams.

Data from different sources may need to be searched, matched and interpreted before it can support decisions about individual healthcare professionals (HCPs) and healthcare organisations (HCOs). Aggregated data can also make it difficult to understand the individual customers behind broader market activity.

That is the gap the new Inception CRM and Healthrix partnership is designed to close for pharma companies operating in the Czech and Slovak markets. Healthrix, the healthcare data analytics division of TME Solutions, provides detailed local healthcare intelligence, while Inception CRM connects that intelligence to the HCP and HCO records, workflows and commercial activity teams use every day.

Healthrix provides provider-level Czech and Slovak healthcare data and intelligence from trusted national sources including ÚZIS and NCZI. Inception CRM consolidates relevant Healthrix data into HCP and HCO customer profiles so commercial teams can use that intelligence for targeting, planning and customer engagement.

The result is a customer-level view that can support targeting and planning, provide direct access to detailed Healthrix reporting, guide next-best actions and become richer as commercial teams add their own first-party data. 

Why healthcare data needs to be commercially usable

Healthcare data is an important input into commercial decision-making in pharma. It can help companies understand markets, identify relevant HCPs and HCOs, plan territories, and determine where commercial teams should focus their attention.

The critical factor is turning available healthcare data into information a commercial team can actually use.

Healthcare data may come from multiple sources and in different structures. Relevant information about the same doctor or healthcare organisation can require searching, matching, mapping, analysis, and interpretation before a commercial user has a useable customer-level picture.

This creates a gap between having healthcare intelligence and being able to use it during everyday commercial activity.

A commercially useful approach closes that gap by connecting relevant external healthcare intelligence to the individual HCP and HCO records where targeting, planning, engagement, and follow-up actually take place.

Why provider-level HCP and HCO intelligence matters

Aggregated or brick-level healthcare data can be valuable for understanding markets and geographic patterns, but commercial pharma teams ultimately engage with individual customers.

A territory may contain brick-level doctors or healthcare organisations with very different commercial relevance. Looking only at aggregated activity can hide those crucial differences.

Provider-level HCP and HCO intelligence gives commercial teams greater granularity. Instead of treating several customers as a single geographic unit, teams can analyse individual healthcare professionals and organisations and use that information when making strategic commercial decisions.

Healthrix, the data analysis division of TME Solutions, can take that analysis further by segmenting healthcare providers according to factors such as specialty, treatment behaviour, and patient profile. This gives commercial teams a stronger basis for distinguishing between providers that may appear similar in a conventional customer list but represent very different commercial opportunities.

This provides a stronger basis for:

• HCP and HCO segmentation
• Customer targeting and prioritisation
• Territory planning
• Call and engagement planning
• Commercial analysis
• Future strategy

Clean, structured, provider-level healthcare data gives pharma reps and other users the ability to connect relevant healthcare intelligence to the specific customer the commercial team is working with — and all of that right inside Inception CRM.

How Healthrix provides Czech and Slovak healthcare intelligence

Healthrix is the healthcare data analytics division of TME Solutions. It provides detailed Czech and Slovak healthcare market data and analytics designed to turn healthcare activity into useful market intelligence.

Its work draws on healthcare data sources including ÚZIS in Czechia and covers areas such as medicines, healthcare providers and workplaces, diagnoses, specialties, patient populations and healthcare activity. Healthrix uses this data for provider mapping and segmentation, patient and treatment analysis, market mapping, forecasting, and launch and commercial analytics.

For commercial teams, this can help answer much more specific questions about the market: which providers are most relevant to a particular therapeutic area, how providers differ by specialty, treatment behaviour or patient profile, where commercial opportunities are concentrated, and how customers should be segmented and prioritised.

This gives pharma companies a detailed external view of their Czech and Slovak markets before that intelligence is connected with customer records and commercial activity inside the CRM.

How Inception CRM turns Healthrix data into customer-level intelligence

Inception CRM integrates licensed Healthrix data into a purpose-built pharma CRM.

Rather than requiring commercial users to search through separate information and establish the relationship between different data points themselves, Inception CRM matches and consolidates relevant Healthrix intelligence into individual HCP and HCO customer profiles.

This means a rep looking at an HCP can immediately see relevant customer intelligence in the context of that customer’s individual CRM record.

The same profile can bring together:

• Relevant Healthrix healthcare intelligence
• Customer segmentation and targeting information
• Previous visits and call reports
• CLM activity
• Approved email activity
• Customer notes
• Samples or orders, where applicable
• Other first-party commercial information

That changes the role of healthcare data. It’s no longer simply an external source to analyse separately; it becomes part of the customer context used during all commercial planning and execution.

From customer intelligence to next-best action

Commercial teams do not only need to know what the data says, it’s very important that they are easily able to decide what to do with it.

Once relevant healthcare intelligence is consolidated against individual HCP and HCO profiles, Inception CRM can apply deterministic business logic to support commercial decision-making and next-best actions.

For example, customer intelligence can contribute to decisions about which HCPs to prioritise, what action should follow a previous interaction, or how a customer should be approached within an agreed commercial strategy.

This creates a progression from:

healthcare data → customer intelligence → commercial decision → action

The objective is not to replace commercial judgement. It is to give teams a consistent, data-informed basis for deciding what should happen next.

Access detailed Healthrix reporting directly from the customer record

Not every piece of healthcare intelligence needs to be displayed permanently on an HCP or HCO profile.

Inception CRM can surface the most important customer information directly while providing access to more detailed Healthrix reporting when users need to investigate further.

From an HCP or HCO customer record, a user can open the relevant preconfigured Healthrix reporting view for that customer. Inception CRM passes the necessary customer and user parameters so the appropriate report is loaded without requiring the user to search manually for the customer and configure the report again.

This creates two levels of information:

Immediate customer insight: key intelligence available directly in the CRM profile.

Detailed analysis: customer-specific Healthrix reporting available when deeper investigation is required.

Commercial users can therefore move from the customer record to detailed healthcare analytics without disconnecting the analysis from the customer they are working with.

Why CRM integration matters for field teams

A healthcare dataset and a CRM solve different problems.

External healthcare data helps a pharma company understand the market and its customers. A pharma CRM manages the commercial relationship with those customers: targeting, activities, calls, content, email, follow-up and analysis.

Keeping those two environments separate places work between them.

A rep may need to find a customer in one system, interpret the available intelligence, locate the corresponding CRM record and then decide what action to take. At scale, those additional steps make valuable data harder to use consistently.

Connecting healthcare intelligence directly with HCP and HCO records reduces that gap. The information appears where commercial teams already plan and execute their work.

For field teams, that can mean less searching and record matching and a clearer customer context before the next interaction.

First-party HCP and HCO knowledge becomes more valuable over time

External healthcare intelligence provides a starting point. The organisation’s own customer interactions add another layer of knowledge that competitors cannot simply purchase.

Every meaningful interaction can add information to an HCP or HCO profile: what was discussed, which product was promoted, how the customer responded, what content was presented, what questions were raised and what should happen next.

Over time, the customer profile can therefore combine two different forms of intelligence:

External healthcare intelligence from Healthrix provides information about the HCP, HCO and wider healthcare market.

First-party commercial knowledge from the pharma company’s own interactions records what its teams have learned about that customer.

This distinction matters. Competitors may be able to license external healthcare data, but they do not have access to the commercial knowledge accumulated through another company’s customer relationships.

The value of the CRM therefore increases as teams continue to use it and enrich their HCP and HCO profiles.

Healthcare data can also accelerate pharma CRM implementation

Customer data is one of the practical challenges of implementing a new pharma CRM.

The advantage isn’t limited to having customer records ready sooner. Healthrix also supports launch and commercial analytics such as market mapping, opportunity sizing, forecasting and customer prioritisation. That means commercial teams can enter a launch with a more developed view of where the opportunity sits and which parts of the provider landscape deserve the greatest attention.

Without a usable starting dataset, commercial teams may need to spend time preparing customer records before they can begin territory planning, targeting and field execution.

The Healthrix and Inception CRM partnership gives Czech and Slovak pharma companies another route: license relevant Healthrix healthcare data and integrate it with Inception CRM so that external healthcare intelligence can be consolidated against the HCP and HCO profiles used by commercial teams.

For existing Inception CRM customers, licensed Healthrix data can also be added to the current CRM environment.

Inception CRM customers can access Healthrix data at preferential partnership pricing.

Healthrix + Inception CRM vs. a standalone healthcare dataset

The difference is not simply the source of the healthcare data. It is what happens between obtaining that data and using it commercially.

For pharma companies, this is the distinction between having healthcare data and making healthcare data part of the commercial operating model.

Turning Czech and Slovak healthcare data into commercial action

The commercial value of healthcare data depends on more than the quantity of information available.

The data needs to be sufficiently detailed to support customer-level decisions, connected to the HCPs and HCOs commercial teams actually work with, accessible during everyday workflows and capable of informing what happens next.

Healthrix provides detailed Czech and Slovak healthcare intelligence. Inception CRM connects that intelligence to individual HCP and HCO customer profiles, commercial workflows and first-party interaction history.

That creates a continuous cycle:

healthcare intelligence → customer understanding → commercial action → first-party knowledge → stronger future decisions

For Czech and Slovak pharma companies, that is what turns healthcare data from an external information source into an actionable commercial asset.

Christopher Crawford is Head of Marketing at Inception CRM. He writes about the real-world strengths, weaknesses, and trade-offs of pharma CRM and B2B software, helping teams make clearer, more informed technology decisions.

FAQ:

The post How to turn Czech and Slovak healthcare data into actionable commercial strategy appeared first on Inception CRM.

Medical rep call reporting (sometimes called pharma call reporting or daily call reporting/DCR) turns field interactions that medical reps have with doctors, HCPs, and HCOs into reusable customer data for follow-up, targeting, segmentation, analysis, commercial insight, and future engagement.

Good daily call reporting captures enough structured information to support analysis without creating unnecessary admin for reps, while preserving free-text context where it adds value.

Repeated HCP question cadences, including skip logic where appropriate, can also help track how doctors’ attitudes towards products change over time.

A well-designed reporting model strengthens the company’s first-party HCP data and gives commercial teams a clearer basis for future action.

What is a medical rep call report?

A medical rep call report (sometimes called a daily call report) is a record of an interaction between a pharmaceutical sales rep and an HCP, HCO or other relevant customer. It normally records who the rep contacted, the purpose of the interaction, what was discussed, the outcome and any follow-up.

Depending on the company and market, the report may also include products discussed, approved content presented, samples supplied, orders, questions raised and information gathered during the interaction.

Each report should form part of the customer’s interaction history so that a rep preparing for the next visit can see what happened previously without reconstructing the account from memory, email, or disconnected notes.

What is a Daily Call Report (DCR) in pharma?

A Daily Call Report, usually shortened to DCR, records a medical representative’s field activity. The term DCR is widely used across parts of Asia and the Middle East and may cover doctor visits, products discussed, samples supplied, follow-ups, and other activities completed during the day.

Some pharma companies use DCR to describe the full daily activity record, while others use it for the individual doctor or customer visit record.

Is a DCR the same as a medical rep call report?

Not always. A Call Report usually refers to one customer interaction, while a Daily Call Report may combine several interactions into the pharma sales rep’s record for the day.

Different companies use the terms differently, so each interaction still needs to be identifiable, linked to the correct HCP or HCO record, and available later for reporting and planning.

What should a medical rep call report include?

A medical rep call report should contain enough information to understand the interaction, record the outcome, plan any follow-up, and preserve any HCP information that may affect future engagement. The exact fields depend on the company, market, customer type, and the purpose of the call.

Not every field belongs on every report. If no samples were discussed, the rep shouldn’t have to work through sample questions, while a call with an HCO procurement contact may need different questions from a routine HCP visit.

The report should change according to the type of interaction rather than present every possible field every time.

What should be structured in a field rep call report and what should stay as free text?

Information that needs to be compared, filtered, counted, or reused elsewhere in the CRM should usually be structured, which makes products discussed, interaction type, call outcome, and follow-up status easier to analyse across large numbers of calls.

Free text is better for context that can’t be predicted in advance.

For example:

An HCP asked whether additional evidence is available for patients over 70 years of age and wants to revisit the subject after the hospital’s protocol review.

That information may influence the next call but forcing every possible HCP observation into a predefined list would make the form cumbersome. At the other extreme, if products, outcomes, objections, and follow-ups all disappear into notes, the company collects information that’s difficult to compare across hundreds or thousands of calls, making any analysis far harder to do.

Best practices are to structure repeated information and use notes for context that genuinely needs explanation.

What does a good medical rep call report look like?

A rep visits an endocrinologist who has previously discussed Product A. During the visit, the HCP asks about its use in older patients, reviews approved content, and requests additional tolerability information for a later discussion.

The same interaction could be recorded in three ways:

The useful version records the information another rep, manager or colleague may need later without turning the call report into a transcript of the meeting.

The report only needs the parts of the conversation that will still be useful after the meeting.

When should medical reps complete their call reports?

Medical reps should record the essential details either during the call itself or soon after the interaction, then be able to complete or correct the report later the same day if needed.

Field work rarely allows every call to be documented in full immediately since reps may have another appointment, need to travel between accounts, or work in places where mobile connectivity is unreliable. Forcing a rep to finish every field before moving on can encourage rushed reporting, while leaving all reporting until several days later means small details disappear, notes become generic and outcomes get reconstructed from memory.

Reps need to be able to capture the important information close to the interaction, return to the record later if necessary, and finish the working day with the required reporting complete.

Reps also need offline reporting in hospitals, rural territories and other places where mobile connectivity is unreliable, so the interaction can be recorded immediately and synced later.

How much information should a medical rep call report require?

Every mandatory field should support a real use, so before adding a question to a call report the company should know:

• Who uses the answer
• What decision, analysis or workflow it supports
• Whether the information is required for every relevant interaction

A field that nobody uses after submission is difficult to justify as mandatory.

Conditional questionnaires reduce unnecessary fields. A rep who selects “samples provided” can be shown the relevant sample fields, while someone who did not provide samples does not need to see them. The same logic can apply to account type, product, outcome, channel, and other details.

Some HCP questions are deliberately repeated at defined intervals so changes in attitude can be tracked over time. A rep might periodically ask how an HCP feels about a product using a structured response such as positive, neutral, or negative.

The questionnaire can then use skip logic to show different follow-up questions depending on the answer. If the HCP selects “neutral,” for example, the rep can be shown a follow-up asking why. A different follow-up can appear for a positive or negative response.

Repeating the same core question at defined intervals creates comparable data across interactions, while skip logic captures the reasons behind each response through relevant follow-up questions.

Adding more questions may increase the number of data points collected while reducing the care reps take over each answer.

How does call reporting fit into a pharma company’s data strategy?

Medical rep call reports are an important source of first-party HCP data because every interaction can add something to the company’s understanding of the customer: subjects discussed, areas of interest, objections, follow-up requirements, engagement history, preferred channels, or other commercially relevant information.

The structure of the call report determines whether those observations can be reused or remain buried in individual notes.

A company deciding what to collect should work backwards from the decisions the data will support.

More fields do not necessarily produce a better customer database because the information still has to be defined consistently, completed with reasonable accuracy and used afterwards.

What is the difference between a call record and an HCP insight?

A call record describes what happened, while an HCP insight records information that may affect a future decision or interaction.

For example:

Call record: Product A discussed.

HCP insight: HCP wants more information about tolerability in older patients before discussing wider use.

The first records activity, while the second may influence the next discussion, follow-up, or way the HCP is approached. Both are useful, but only the second can directly change future HCP targeting, follow-up, or call preparation.

Which call report data should update the HCP profile?

Call report information should update the HCP profile when it describes something likely to remain useful beyond that one interaction, such as a confirmed channel preference, a customer classification or another structured attribute used for segmentation.

Other information should stay with the individual interaction. A question raised in one meeting, a temporary account issue, or a short-term follow-up may be useful without becoming a permanent HCP attribute.

Without that distinction, the customer profile can fill up with old observations and temporary information that later gets mistaken for current fact.

How long should call report data remain current?

Some HCP information needs periodic review: specialty may remain stable for years, while treatment interests, channel preferences, account priorities or objections can change much sooner.

If call report data feeds segmentation or targeting, companies need to know which fields represent durable attributes and which may need reconfirmation, otherwise old customer information can continue influencing activity after it has stopped being accurate.

How do field rep call reports improve the next HCP interaction?

Call report data should help the rep prepare the next HCP interaction by showing previous discussions, questions, content presented, commitments made and any open follow-up.

Information from one call should feed the HCP history, inform pre-call planning and then be updated after the next interaction.

If an HCP requested a particular piece of approved information, that request should still be visible when the next call is planned. If the same HCP repeatedly asks about one subject and shows little interest in another, the interaction history can help the rep prepare a more relevant discussion.

Reps are more likely to use the CRM properly when the information they enter improves their own customer history and planning rather than disappearing into management reporting.

How do managers use medical rep call report data?

Managers use call report data to understand activity, coverage, execution and follow-up across territories and teams.

This information can show where activity differs from the plan, where follow-up is being missed or where the same customer question is appearing repeatedly across a market.

Location data may also be relevant for some field-force models, but proof that a rep attended a location is only one possible use of call reporting.

How should pharma companies standardise call reporting across different markets?

Pharma companies operating across several countries need enough consistency to compare call report data while still allowing local teams to record market-specific information.

Core fields and definitions should usually be shared, while products, questionnaires, classifications, and workflows may differ locally.

Using the same field name everywhere does not solve the problem if each market defines it differently. If “successful call” means a completed visit in one country and a specific HCP response in another, a regional report will compare two different measures under the same heading.

Companies operating across markets such as France, the UAE, Singapore, and Australia may share the same basic interaction model while still allowing local teams to configure products, activities, and questions.

How should medical rep call reports handle remote calls?

Remote calls should be recorded in the same HCP interaction history as face-to-face visits, with the report identifying the channel and recording the same core information where relevant: HCP, topic or product, approved content presented, response, outcome, and follow-up.

A phone or video interaction should not end up in a separate customer history simply because the channel changed.

If e-detailing is used during the call, the record can also show which approved digital content was presented.

What are the most common problems with medical rep daily call reporting?

Most call reporting problems come from forms that ask for too much, capture information in the wrong format or collect data that is never used.

Poorly designed call reports change rep behaviour: forms that waste time eventually produce weaker data, even when the original aim was to collect more information.

How should pharma CRM support pharma rep call reporting?

Pharma CRM should reduce unnecessary data entry while keeping the resulting information usable after the report is submitted.

Every call should link to the correct HCP or HCO record, with repeated information captured through structured fields while notes remain available for context that cannot be reduced sensibly to a fixed value. Questionnaires should adapt to the interaction using skip logic instead of showing every possible field on every call.

Relevant answers can also update customer information where appropriate, while previous interactions remain available for planning the next contact.

Field teams need offline access where connectivity is unreliable, and reps should be able to complete or correct records during the working day rather than being pushed through an unnecessarily rigid close-call process.

Related activities should remain connected because a single visit may include a call report, approved content, samples, an order or a follow-up task; keeping those records together creates a clearer HCP history than storing them separately.

Remote and face-to-face interactions should feed the same customer record.

Inception CRM supports this model through dynamic questionnaires, linked HCP/HCO records, offline reporting, and connected interaction histories.

Can medical rep call reporting be automated?

Some parts of call reporting can be captured automatically because the CRM may already know the HCP, date, interaction type, content shown or other activity metadata, and asking the rep to enter the same information again adds work without improving the record.

Other parts depend on the rep’s judgement, including what the HCP asked, how the discussion ended, what follow-up is needed or which observation is worth preserving.

Automation should remove duplicate entry and leave the rep to record information the system could not know by itself.

What should happen if an HCP reports an adverse event or product complaint?

If an HCP reports a possible adverse event or product complaint during a sales interaction, the rep should follow the company’s approved pharmacovigilance or product-quality procedure and any applicable local requirements.

A call report should not be treated as a substitute for the required safety or quality reporting process.

What should pharma companies look for in call reporting software?

Call reporting software should support field work, customer history and the company’s wider data model.

Key takeaways on medical rep call reporting

• Medical rep call reports should capture information that remains useful after the interaction, not simply prove that a visit happened.
  
• Repeated information should be structured for analysis, while free text should preserve context that predefined fields can’t capture.
  
• Repeating structured HCP questions at defined intervals, with skip logic for relevant follow-ups, can track changes in HCP attitudes and create useful first-party commercial data.
  
• Call-report data should feed the wider HCP record, follow-up, targeting, segmentation and future call planning rather than remain isolated in activity logs.
  
• To increase rep adoption, pharma CRM should make reporting easier for reps through relevant questionnaires, offline access, connected interactions and minimal duplicate entry.

Christopher Crawford is Head of Marketing at Inception CRM. He writes about the real-world strengths, weaknesses, and trade-offs of CRM and B2B software, helping teams make clearer, more informed technology decisions.

FAQ: Medical Rep Call Reporting

The post Medical rep daily call reports: what data to capture and how pharma daily call reporting works appeared first on Inception CRM.

Transparent pharma CRM pricing gives commercial teams a fairer starting point. It helps them qualify vendors, compare total costs against their budget, prepare stronger business cases, and enter sales discussions with fewer unknowns.

Introduction

Transparent pharma CRM pricing helps buyers compare licence costs, implementation fees and total cost of ownership before they commit to a sales process. But there’s a recurring problem in the pharma CRM sales cycle. It is this: A buyer can usually find out what a platform can do functionally long before learning what the CRM platform actually costs.

Pharma CRM vendors will often explain field-force management, HCP engagement, approved email, sample accountability, reporting, compliance and analytics in considerable detail, then instead of visible and transparent pricing, the buyer will just see a button marked “Contact sales”.

So the buyer is expected to book a call, go through the discovery process, explain the company’s commercial model, discuss user numbers, outline the markets involved and perhaps sit through a demonstration before anyone will even say whether the software costs €50,000 or €500,000. Insufferable, and frankly, not logical from the buyer’s perspective.

There are legitimate reasons why a pharma CRM project can’t always be reduced to one fixed price. Implementation scope varies and data migration can be straightforward or difficult. Integrations, validation requirements, markets, languages and business processes all affect the work involved.

But none of that explains why the licence price itself has to be treated like commercially sensitive intelligence.

Hidden pricing transfers work and risk from the vendor to the buyer. It makes early comparison harder, weakens internal budgeting and leaves commercial teams trying to evaluate products without one of the most important pieces of information. This is especially true of SME and mid-market pharma companies who often work with a leaner commercial model.

Software buyers are increasingly resistant to this. Gartner reported in 2025 that 86% of surveyed buyers had cancelled or delayed at least one software deal because of pricing or packaging issues.

Evaluating pharma CRM pricing simply shouldn’t require that amount of detective work right from the start.

Why do pharma CRM vendors hide their pricing?

The explanation most often given is that enterprise software is too complicated for public pricing.

There is some truth in that. A pharmaceutical company deploying CRM for 30 representatives in one market won’t have the same requirements as a company operating across 15 countries, with multiple business units, legacy databases, ERP integrations and separate medical and commercial teams.

A responsible vendor needs to understand the project before producing a final implementation quote.

But licence pricing is rarely unknowable. Nor is it impossible to publish typical implementation costs, explain which services are included or show how costs change when users, modules and markets are added.

More often, hidden pricing protects the vendor’s sales process.

This is designed to prevent prospects from rejecting the platform before a salesperson has had the opportunity to establish its purported value.

It allows the vendor to gather information about company size, budget, urgency and alternatives before giving a figure. It also leaves more room to vary pricing and packaging between customers.

Employers have long disliked workers comparing salaries for much the same reason software vendors dislike buyers comparing prices: the person setting the number benefits when everyone else is kept guessing.

That doesn’t mean every vendor withholds pricing for cynical reasons. Some have complicated packaging. Others sell through partners or configure each contract differently. A few may genuinely worry that a bare price will be misleading without an explanation of what sits behind it.

The answer, however, isn’t to publish nothing. It’s to publish enough information for buyers to understand the likely financial commitment and then explain what may change it.

G2 has argued that vendors often fear a publicized number will deter buyers before the product’s value has been established. Yet the same lack of information can damage trust and force buyers further into the sales process before they know whether a viable deal exists. 

How does lack of pharma CRM pricing transparency affect buyers?

The first problem is basic qualification. A commercial operations director may be asked to identify three suitable pharma CRM platforms for the next budget cycle. User numbers are known, the required modules have been agreed and procurement has set an approximate ceiling. Two of the shortlisted vendors provide no public prices, leaving the project team to arrange calls simply to find out whether either platform belongs on the list.

When the figure finally arrives above budget, the buyer hasn’t only discovered that the software is unsuitable, they’ve discovered it way later than was necessary.

Hidden pricing also makes comparison unreliable. Buyers can compare product pages, implementation claims and feature lists, but they can’t judge value without knowing what each package costs and what the initial price excludes.

A €70 per-user licence that includes the required pharma CRM modules may represent better value than a €50 licence that requires separate contracts for approved email, CLM, events, analytics or support.

A more expensive platform may still be the right choice, but any comparison needs to include the same factors on both sides for it to be a meaningful comparison.

Compare opaque and transparent pharma CRM pricing

The second problem appears when the project owner tries to build an internal business case.

An SFE manager may know the number of users, countries, teams and workflows involved but still be unable to provide finance with a credible estimate because the licence cost is undisclosed and implementation is described only as “dependent on scope”.

This puts the buyer in a ridiculous position. They need internal approval to progress the project, yet need to progress the project before the vendor will provide enough information to request approval. It’s a sales process designed as a bureaucratic loop.

The resulting spreadsheet fills up with ranges, assumptions and lines marked “TBC”. The CRM proposal then appears less developed than it actually is because the company selling the system has withheld the numbers required to complete it.

Pricing secrecy also increases the risk of sunk-cost pressure. Once a team has attended demonstrations, completed security questionnaires, scored the shortlisted products and presented a preferred vendor to management, restarting the process becomes inconvenient.

If additional module, integration or support costs appear at that stage, the buyer may accept terms they would have challenged earlier because changing direction now carries its own internal cost.

By this point, the buyer is no longer judging the quote on its merits. They’re also calculating the embarrassment, delay, and internal politics involved in starting all over again. They may even fear for their job, rightly or wrongly.

Mid-sized pharmaceutical companies are particularly exposed. Larger enterprises may have dedicated procurement teams, external consultants and access to software pricing benchmarks. A mid-market company may rely on an SFE director, commercial operations lead or IT manager who is already handling the project alongside a full-time role.

The less buying support a company has, the more damaging it is to make basic commercial information difficult to obtain.

Is licence price the total cost of a pharma CRM?

Published licence pricing is useful, but it doesn’t tell the whole story and certainly doesn’t represent the full cost of a pharma CRM.

The total cost of a pharma CRM can include implementation, configuration, data migration, integrations, validation, training, support, additional environments, new markets and future development. Buyers also need to understand whether common pharma capabilities are included in the base product or licenced separately.

A low headline figure can be as unhelpful as no figure at all when the package has been stripped of the functionality required to operate it.

Pharma CRM licence pricing and total cost of ownership

The useful question is not simply, “What is your price per user?”

Buyers need to ask what that price includes, what is compulsory, what varies by scope and which costs are likely to appear over the next three years.

This distinction matters because pricing transparency doesn’t mean cheap pricing, it also means predictable pricing.

A buyer may knowingly select the more expensive system because it offers better functionality, stronger service or lower implementation risk. Transparency allows that decision to be made with a reasonable understanding of the financial commitment.

What should transparent pharma CRM pricing include?

A vendor doesn’t need to predict the final cost of every possible implementation on its website. It should still provide enough information for a buyer to decide whether to continue.

At minimum, transparent pharma CRM pricing should explain the following:

This is enough to let a buyer perform an initial pharma CRM pricing comparison without pretending that every project is identical.

It also improves the first sales conversation. When buyers already understand the likely cost and package, the discussion can concentrate on workflows, technical fit, implementation and outcomes rather than spending the opening half-hour trying to establish whether the platform is affordable.

G2’s 2026 buyer research also points to the growing importance of structured commercial information for AI-assisted software evaluation. Pricing logic, contract terms, implementation requirements, renewal options and expansion paths are among the inputs buyer systems increasingly need to assess vendors properly. 

In other words, pricing opacity no longer inconveniences only the person browsing the website, it also makes a vendor harder for procurement tools and AI systems to evaluate, compare and recommend.

Why does Inception CRM publish its pricing?

Inception CRM publishes its licence prices because pharma CRM buyers should be able to assess commercial and budget fit before committing time to a sales process.

The platform is designed for mid-market pharmaceutical companies that need specialist pharma functionality without the cost and administrative burden associated with the largest enterprise systems like Veeva and Salesforce.

Inception CRM licence plans currently range from €40 to €100 per user per month. For current plan pricing, included functionality and package comparisons, see the Inception CRM pricing page.

Of course, publishing prices doesn’t completely remove the need for discovery. A vendor still needs to understand data, integrations, configuration, reporting, validation and rollout requirements before confirming an implementation proposal.

But already knowing the price of licences changes the purpose of that conversation.

The buyer arrives knowing the licence cost and which package appears appropriate for them. The vendor can then quickly determine what the project actually requires rather than both sides existing in a fog of ongoing ambiguity.

This approach also reflects a simple view of partnership. A serious technology vendor should help customers decide whether its platform is suitable, including when the answer is no.

There is little value in pulling a company through several stages of evaluation only to reveal that the expected spend, implementation model or contract structure was never compatible with its needs. That’s how bad projects are born.

What questions should buyers ask pharma CRM vendors about pricing?

Before comparing quotes, buyers should ask vendors to define the boundaries of each figure they provide.

Does the per-user licence include every module shown in the demonstration? Are support, updates and validation included? Will the company pay separately for HCP records, calls, data updates, emails or transactions? Which implementation tasks are covered, and which will be billed as additional consultancy?

Buyers should also establish what happens after launch. The initial contract may work for one country and sixty users, but costs can change considerably when a second market, another business unit or a new integration is added.

A useful three-year cost estimate for a pharma CRM should include licences, implementation, migration, integrations, support, likely expansion and any modules the company expects to adopt later.

The vendor should be able to explain the pricing model in ordinary language. When a quote requires several calls to understand, the problem is rarely confined to the quote itself.

Pharma CRM buyers deserve enough information to decide

Pharma CRM procurement will never be as simple as ordering a standard consumer product. The software touches regulated processes, customer data, field execution, reporting and commercial operations, and the work required to deploy it varies between companies.

That complexity makes pricing clarity more important, not less.

Buyers don’t need every project reduced to a single universal figure. They need a credible range, a clear account of what is included and an honest explanation of what may increase the cost.

Without that information, vendors ask buyers to invest time, disclose requirements, and begin internal planning before they can judge whether the platform is financially realistic.

Transparent pharma CRM pricing gives commercial teams a fairer starting point. It helps them qualify vendors, compare total costs, prepare stronger business cases and enter sales discussions with fewer unknowns.

Christopher Crawford is Head of Marketing at Inception CRM. He writes about the real-world strengths, weaknesses, and trade-offs of CRM and B2B software, helping teams make clearer, more informed technology decisions.

FAQ: Transparent pharma CRM pricing

The post Transparent pharma CRM pricing: why vendors hide costs and what buyers should know in 2026 appeared first on Inception CRM.

Most pharmaceutical companies already know which HCPs operate within the markets they serve. They have access to customer databases, prescribing data, territory knowledge, long-standing field relationships and years of engagement history inside their pharmaceutical CRM.

But having more customer information doesn’t necessarily translate into better engagement. Deloitte found that while 82% of life sciences executives were satisfied with their customer engagement strategies, only 28% of HCPs felt those strategies met their needs.

So how do pharma companies decide which of those healthcare professionals should receive the greatest commercial attention — and through which channels, at what call frequency and with what CLM content?

Field teams cannot engage every HCP with the same frequency or depth, and treating a complete customer database as though every HCP is a priority just spreads commercial efforts too thinly.

The real value of HCP targeting lies in helping pharmaceutical companies decide where their limited field time and commercial resources are most likely to have an impact.

What is HCP targeting?

HCP targeting in pharma is the process of identifying and prioritising the healthcare professionals who should receive the greatest commercial attention.

Effective healthcare professional targeting combines customer potential, clinical and commercial relevance, organisational influence, accessibility, previous engagement and strategic fit rather than relying on prescribing volume alone. The strongest targeting models connect HCP prioritisation with segmentation, territory planning and field execution, while continuously using new CRM and engagement data to keep priorities current.

A pharma CRM supports this process by providing a trusted HCP record, visibility into customer activity and the commercial intelligence needed to improve future targeting decisions.

Why HCP targeting has become more difficult

As the amount of healthcare data available to commercial teams has grown, this process has become even more complicated.

A company may have detailed records for thousands of doctors and healthcare organisations, but a larger database doesn’t automatically provide a clearer view of commercial priority. In truth, it can make target customers even harder to identify.

The data also come from various sources and are scattered across multiple silos.

External healthcare data may provide the basic market picture. CRM records show previous calls, content use, email activity, samples and event attendance, alongside the knowledge accumulated by field teams. Prescribing data adds another layer, though it rarely explains the full role an HCP plays within a healthcare organisation or treatment pathway.

Somewhere inside all of that information is the answer to a practical commercial question: which doctors and other healthcare professionals should the organisation focus on now?

Why HCP targeting affects commercial execution

The quality of this targeting process affects far more than the target list itself. Territory planning depends on it because territories can only be balanced properly when the organisation understands which customers are higher priority and which aren’t.

Call planning depends on it because reps need a credible data-backed reason to give one doctor more attention than another.

Reporting depends on targeting too, since high activity levels mean nothing when activity is focused on HCPs with limited or no commercial relevance.

Yet HCP targeting often stays stagnant for longer than the market conditions behind it.

Target lists are often agreed during an annual or quarterly planning cycle and then used as the basis for field execution over the months that follow.

During that time, doctors move between workplaces, prescribing patterns change, healthcare organisations reorganise services, and product priorities move with the needs of the business. A targeting model that was accurate when it was approved becomes progressively less useful without ever appearing obviously wrong.

That gradual decline is one of the reasons weak targeting can be difficult to spot.

Field activity carries on, reps make their calls, and the CRM continues collecting data. Nothing necessarily fails in a dramatic way, so commercial efforts just become fuzzy and disconnected from reality.

This is also why HCP targeting can’t be treated as a purely analytical exercise completed by headquarters and handed to the field. Data can indicate customer potential, prescribing behaviour, speciality, organisational role or previous engagement, but those indicators still need to be interpreted within the commercial context of the company, product, territory and market.

An HCP with low prescribing volume may influence treatment decisions across a wider network, while another may appear commercially attractive in a dataset but stay difficult to access in reality.

Some customer relationships may matter because of their future potential rather than their current activity.

The targeting process has to accommodate those differences without becoming so complicated that nobody can apply it consistently.

Takeaway:

Targeting shapes territory design, call planning and performance measurement, so outdated priorities can quietly weaken field execution without creating an obvious operational failure.

Why more healthcare data hasn’t made HCP targeting easier

More data doesn’t mean easier or more impactful HCP data analysis.

The pharmaceutical industry has access to more healthcare data than it has ever had before, yet many commercial teams still struggle to establish a consistent view of which HCPs matter most.

Part of the problem is that healthcare data is collected for different purposes.

A provider directory may confirm that a doctor exists and where they work, and prescribing data may indicate commercial potential. CRM activity shows what the organisation has already done, while information from the field adds context that external datasets can’t provide.

These sources become commercially useful when they support one coherent view of the customer. When they stay fragmented, each department or affiliate can reach a different conclusion using a different version of the same HCP.

The issue becomes especially visible in organisations that have accumulated customer data over several years.

Duplicate records stay in the CRM, workplace details become outdated, segmentation differs between markets, and local customer lists continue running alongside the central database. Commercial teams may have plenty of information, but no single version they trust enough to guide targeting consistently.

More data can also encourage overcomplicated targeting models.

Companies sometimes create large scoring frameworks containing every available variable, then discover that the result is difficult to explain to the people expected to use it.

A model may be analytically impressive while giving a representative very little practical guidance about who to see, how often to engage them or why their priority has changed.

Effective HCP targeting needs enough depth to reflect commercial reality without losing sight of field execution.

Takeaway:

The objective is not to produce the most sophisticated customer scoring matrix. It’s to give the organisation a reliable and current basis for deciding where commercial attention should go and why.

What effective HCP targeting needs to account for

The strongest targeting models begin with reliable customer data, but they don’t stop there. Pharmaceutical companies still need to decide which commercial signals matter, how those signals should be weighted and how the resulting priorities will be used by the field.

That becomes difficult when targeting is reduced to a single measure such as prescribing volume. Volume can be useful, but it only captures part of the customer picture. It may say little about an HCP’s influence within a hospital, their role in treatment decisions, their access to relevant patient populations or the likelihood that a relationship will develop over time.

Commercial relevance is rarely visible through one number.

A useful targeting model usually draws on several sources of information and combines them in a way that reflects the company’s current priorities. Common criteria include customer potential, commercial relevance, influence, accessibility, previous engagement and strategic fit.


Common HCP targeting criteria

No single criterion should determine customer priority on its own. The value comes from combining profile data, behavioural data, commercial data and field knowledge in a way that reflects the company’s product, market and current objectives.

The criteria may differ by product, therapeutic area, lifecycle stage or market. A mature brand may require a different customer focus from a new launch. A specialist product may depend heavily on a small group of influential clinicians, while a broader portfolio may require more attention across community care, pharmacy networks or healthcare organisations.

This is why HCP targeting can’t be copied wholesale from one pharmaceutical company to another. The process has to reflect how the organisation actually competes.

Takeaway:

Effective targeting combines multiple commercial signals because prescribing volume or any other single measure cannot capture an HCP’s full value, influence or accessibility.

HCP potential needs commercial context

Customer potential is often central to HCP targeting, but it needs to be defined carefully.

Prescribing data can indicate current value, yet current value and future opportunity are not always the same. An HCP may be highly active but already well served by competitors. Another may have lower current volume while working in a growing institution, influencing a larger clinical network or becoming more relevant as treatment pathways change.

The targeting model has to recognise that difference.

Commercial teams also need to understand whether an HCP is reachable. A customer may appear attractive on paper but stay difficult to engage because of institutional access restrictions, limited availability or local market conditions. Ignoring accessibility produces target lists that look strong centrally and perform poorly in the field.

The same applies to organisational influence. Some HCPs shape decisions well beyond their own prescribing activity. Their importance may come from committee membership, leadership within a treatment centre, participation in professional networks or influence over local clinical practice.

None of these factors should replace evidence of commercial potential. They should refine it.

HCP segmentation should guide your HCP engagement strategy

HCP segmentation is useful when it helps commercial teams act differently.

Many organisations create detailed customer segments that describe HCPs accurately but do little to change field behaviour. The labels become part of the CRM record, while representatives continue working from familiar call patterns.

A segment only has commercial value when it influences what happens next.

For example, a high-priority hospital specialist may receive regular face-to-face visits, tailored CLM content and structured follow-up, while a lower-priority community HCP may be engaged mainly through approved email and selected digital content.

That may affect visit frequency, channel selection, message emphasis, follow-up, content use or the amount of field time allocated to a customer. Different customer groups should lead to recognisably different engagement approaches.

If every segment receives the same treatment, the segmentation exercise has added description without improving execution.

The model also has to be understandable. Representatives should know why an HCP has been prioritised and what that priority means in practice. When targeting logic becomes too remote from field reality, local teams begin interpreting it in their own way and consistency quickly weakens.

This is one reason field involvement matters during the targeting process. Representatives often hold useful information about access, relationships, local influence and customer change that doesn’t appear in external datasets. Their knowledge should inform the model without allowing historic habits or personal preference to determine the final list.

The aim is to combine central consistency with local commercial intelligence.

Takeaway:

Segmentation creates value only when different HCP groups receive recognisably different levels and types of engagement.

HCP targeting needs to stay closely connected to territory planning

HCP targeting and territory planning are often handled as separate exercises, even though each depends heavily on the other.

A target list may identify the right customers at company level while producing unrealistic workloads within individual territories. One representative may receive a manageable group of high-priority HCPs, while another is expected to cover a much larger customer population spread across a difficult geography.

The targeting model may be valid, but the plan is not executable.

Commercial teams therefore need to consider the practical distribution of customer priority across the field organisation. That includes geography, travel time, account concentration, access conditions and the frequency of engagement expected for different customer groups.

Good territory planning doesn’t dilute customer priority. It turns that priority into a workload the field can actually deliver.

This becomes especially important when organisations operate across several markets. A centrally defined targeting framework can support consistency, but local market conditions still affect how that framework should be applied. Healthcare structures, prescribing authority, access and customer behaviour vary considerably between countries.

The central model should establish a common commercial logic without forcing every affiliate into an identical execution pattern.

Takeaway:

A commercially valid target list must still be translated into realistic territories, workloads and engagement expectations that field teams can deliver.

Why HCP targeting breaks down inside pharmaceutical organisations

HCP targeting often weakens after the initial model has been approved.

The customer list enters the CRM, territories are assigned and field activity begins. From that point, the organisation may collect large amounts of new information without using it to update customer priority.

Representatives record visits, content use, email engagement, event attendance, samples, follow-up and changes in customer circumstances. Managers review activity and performance. Marketing sees how different messages are received. Yet the target list itself may stay largely unchanged until the next formal planning cycle.

The organisation learns more about its customers while continuing to work from an older commercial view of them.

This problem becomes worse when information sits across disconnected systems. Prescribing data may be held by one team, activity data by another, and field knowledge inside notes that are difficult to analyse. Each source contains part of the customer picture, but no process brings those parts together often enough to influence targeting.

Static ownership also creates friction. Sales, marketing, medical and commercial operations may each have a legitimate view of customer importance, though those views are shaped by different objectives. Without a clear decision process, targeting can become a compromise between departments rather than a coherent commercial model.

The result is often a list that nobody fully owns.

Representatives may then rely on established relationships because those relationships feel more credible than a central score they don’t understand. Managers may focus on activity completion rather than whether the right customers are being engaged. Headquarters sees execution against the approved plan without always seeing how far the plan has drifted from current market reality.

Takeaway:

Targeting weakens when priorities remain static, ownership is unclear and new customer information is collected without being used to update the model.

Turning HCP targeting into commercial execution

The quality of HCP targeting ultimately depends on what happens after the target list has been agreed.

A well-designed targeting model has very little commercial value if it never changes how the organisation works. Customer prioritisation should influence territory planning, call planning, channel selection, resource allocation and, ultimately, the quality of customer engagement. If those activities continue exactly as they did before, the targeting process has simply produced another report.

The strongest commercial organisations reduce that gap through dynamic HCP targeting, treating it as a continuous cycle rather than a periodic planning exercise.

• Commercial data establishes the initial view of the market.
• Field execution tests those assumptions through real customer interactions.
• The knowledge gained from those interactions then improves the next round of targeting.

Each stage strengthens the next.

The role of pharma CRM in effective HCP targeting

A pharma CRM doesn’t decide which healthcare professionals matter most to the business.

That stays a commercial decision.

What the CRM should do is give the organisation a reliable environment in which those decisions can be applied consistently, measured properly and improved over time.

The first requirement is a trusted HCP record

Representatives, managers and commercial operations teams need to work from the same provider-level view of each healthcare professional rather than maintaining separate versions of the same customer across different systems. When customer information stays consistent, discussions about targeting become more productive because teams are evaluating the same commercial reality.

The second requirement is visibility

HCP targeting shouldn’t disappear once the planning cycle has finished. Commercial teams need to understand how targeting is translating into day-to-day execution. Are representatives engaging the customers that were prioritised? Has customer engagement changed since the previous planning cycle? Are important HCPs receiving the level of commercial attention originally intended?

Without that visibility, targeting gradually becomes disconnected from execution.

The third requirement is continuity

Every approved email, CLM presentation, customer meeting, sample request, event and follow-up contributes to the organisation’s understanding of its customers.

Viewed individually, these activities are simply records of commercial execution. Viewed collectively, they become commercial intelligence that can improve future targeting decisions.

That process only works when customer interactions contribute to a shared commercial picture rather than staying isolated within separate systems or individual teams.

The objective is to connect every customer interaction, analyse it together and improve the quality of future commercial decisions.

Takeaway:

A pharma CRM supports targeting by giving commercial teams a trusted customer record, visibility into field execution and a continuous flow of customer intelligence.

Better HCP targeting creates better commercial decisions

Every decision about territory design, field activity, customer engagement and resource allocation depends on the organisation having a clear view of which healthcare professionals deserve commercial attention and why.

If an organisation wants HCP targeting to become an ongoing commercial capability rather than a periodic planning exercise, the supporting technology matters just as much as the targeting methodology itself. A pharma CRM should help commercial teams maintain trusted customer records, apply targeting consistently and turn customer interactions into commercial knowledge that strengthens the next round of decision-making.

That is ultimately the value of effective HCP targeting: greater confidence that limited commercial resources are being directed where they can create the greatest long-term impact.

Christopher Crawford is Head of Marketing at D3S. He writes about the real-world strengths, weaknesses, and trade-offs of CRM and B2B software, helping teams make clearer, more informed technology decisions.

FAQ: EFFECTIVE HCP TARGETING

The post HCP targeting in the pharma industry: How to identify the right healthcare professionals in 2026 appeared first on Inception CRM.